ArticlePDF AvailableLiterature Review

Abstract and Figures

Docosahexaenoic acid,22:6n-3 (DHA) and its metabolites are vital for the structure and functional brain development of the fetus and infants, and also for maintenance of healthy brain function of adults. DHA is thought to be an essential nutrient required throughout the life cycle for the maintenance of overall brain health. The mode of actions of DHA and its derivatives at both cellular and molecular levels in the brain are emerging. DHA is the major prevalent fatty acid in the brain membrane. The brain maintains its fatty acid levels mainly via the uptake of plasma free fatty acids. Therefore, circulating plasma DHA is significantly related to cognitive abilities during ageing and is inversely associated with cognitive decline. The signaling pathways of DHA and its metabolites are involved in neurogenesis, antinociceptive effects, anti-apoptotic effect, synaptic plasticity, Ca2+ homeostasis in brain diseases, and the functioning of nigrostriatal activities. Mechanisms of action of DHA metabolites on various processes in the brain are not yet well known. Epidemiological studies support a link between low habitual intake of DHA and a higher risk of brain disorders. A diet characterized by higher intakes of foods containing high in n-3 fatty acids, and/or lower intake of n-6 fatty acids was strongly associated with a lower Alzheimer's Disease and other brain disorders. Supplementation of DHA improves some behaviors associated with attention deficit hyperactivity disorder, bipolar disorder, schizophrenia, and impulsive behavior, as well as cognition. Nevertheless, the outcomes of trials with DHA supplementation have been controversial. Many intervention studies with DHA have shown an apparent benefit in brain function. However, clinical trials are needed for definitive conclusions. Dietary deficiency of n-3 fatty acids during fetal development in utero and the postnatal state has detrimental effects on cognitive abilities. Further research in humans is required to assess a variety of clinical outcomes, including quality of life and mental status, by supplementation of DHA.
Content may be subject to copyright.
Contents lists available at ScienceDirect
International Journal of Developmental Neuroscience
journal homepage:
Docosahexaenoic acid,22:6n-3: Its roles in the structure and function of the
Rahul Mallick
, Sanjay Basak
, Asim K. Duttaroy
Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Finland
ICMR-National Institute of Nutrition, Hyderabad, India
Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Norway
Docosahexaenoic acid,22:6n-3
Brain development
Endocannabinoid system
Marine oil
Clinical trials
DHA uptake
Brain disorders
Docosahexaenoic acid,22:6n-3 (DHA) and its metabolites are vital for the structure and functional brain de-
velopment of the fetus and infants, and also for maintenance of healthy brain function of adults. DHA is thought
to be an essential nutrient required throughout the life cycle for the maintenance of overall brain health. The
mode of actions of DHA and its derivatives at both cellular and molecular levels in the brain are emerging. DHA
is the major prevalent fatty acid in the brain membrane. The brain maintains its fatty acid levels mainly via the
uptake of plasma free fatty acids. Therefore, circulating plasma DHA is signicantly related to cognitive abilities
during ageing and is inversely associated with cognitive decline. The signaling pathways of DHA and its me-
tabolites are involved in neurogenesis, antinociceptive eects, antiapoptotic eect, synaptic plasticity, Ca
homeostasis in brain diseases, and the functioning of nigrostriatal activities. Mechanisms of action of DHA
metabolites on various processes in the brain are not yet well known. Epidemiological studies support a link
between low habitual intake of DHA and a higher risk of brain disorders. A diet characterized by higher intakes
of foods containing high in n3 fatty acids, and/or lower intake of n6 fatty acids was strongly associated with a
lower Alzheimer's Disease and other brain disorders. Supplementation of DHA improves some behaviors asso-
ciated with attention decit hyperactivity disorder, bipolar disorder, schizophrenia, and impulsive behavior, as
well as cognition. Nevertheless, the outcomes of trials with DHA supplementation have been controversial. Many
intervention studies with DHA have shown an apparent benet in brain function. However, clinical trials are
needed for denitive conclusions. Dietary deciency of n3 fatty acids during fetal development in utero and the
postnatal state has detrimental eects on cognitive abilities. Further research in humans is required to assess a
variety of clinical outcomes, including quality of life and mental status, by supplementation of DHA.
1. Introduction
α-Linolenic acid,18;3n-3 (ALA) and linoleic acid, 18:2n-6 (LA) are
the two essential fatty acids for human health. ALA is available in plant
oils, e.g., walnut, edible seeds (hemp, chia), canola, kukui, axseed oil
and hemp oil whereas its long-chain polyunsaturated fatty acids
(LCPUFAs) eicosapentaenoic acid,20:5n-3 (EPA) and docosahexaenoic
acid, 22:6n-3 (DHA) are obtained from marine sh and oils. In healthy
young adults, consumed ALA from the diet can be converted into EPA
and DHA in little amount (Burdge and Wootton, 2002), but with age,
the conversion capability is reduced (Bradbury, 2011). DHA is, there-
fore, a conditionally essential fatty acid for human health. DHA inu-
ences numerous processes in the body, e.g., signal transduction, mem-
brane structure and function, cellular proliferation, inammation,
Received 22 August 2019; Received in revised form 10 October 2019; Accepted 11 October 2019
Abbreviations: AA, arachidonic acid; AD, Alzheimers disease; ADHD, attention decit hyperactivity disorder; ALA, α-linolenic acid, 183n-3; APOE, apolipoprotein E;
B-FABP, brain-fatty acid-binding proteins; COX, cyclooxygenase; CYP, cytochrome P450; DHA, docosahexaenoic acid,226n-3; EDPs, epoxydocosapentaenoic acids;
EPA, eicosapentaenoic acid,205n-3; EFOX, electrophilic oxo-derivatives; FABP, fatty acid-binding proteins; FAHFA, fatty acid esters of hydroxy fatty acids; FADS2,
delta 6 desaturase enzyme; GPRs, G-protein coupled receptors; H-FABP, heart-fatty acid-binding proteins; HPA, hypothalamus-pituitary-adrenal; HDoHE, hydro-
xydocosahexaenoic acids; HpDHA, DHA hydroperoxides; LCPUFA, long-chain polyunsaturated fatty acids; MaR1, maresin 1; NPD1, neuroprotectin D1; LOX, li-
poxygenases; NO, nitric oxide; PEMT, phosphatidyl ethanolamineNmethyltransferase; p-FABPpm, placental plasma membrane fatty acid-binding protein; PPAR,
peroxisome proliferator-activated receptor; PPAR-α, peroxisome proliferator-activated receptor α; PPAR-γ, peroxisome proliferator-activated receptor gamma;
PUFAs, polyunsaturated fatty acids; RXR, retinoid X receptor specialized pro-resolving mediators
Corresponding author at: Faculty of Medicine, University of Oslo, P.O.B. 1046 Blindern, N-0316, Oslo, Norway.
E-mail address: (A.K. Duttaroy).
International Journal of Developmental Neuroscience 79 (2019) 21–31
Available online 17 October 2019
0736-5748/ © 2019 ISDN. Published by Elsevier Ltd. All rights reserved.
angiogenesis and host of other processes aecting health and disease
(Basak et al., 2013;Bradbury, 2011;Quinn et al., 2010b). DHA meta-
bolites also play a signicant role in dierent biological and cellular
processes. Risk of inammatory disorders, cognitive disorders, in-
sucient brain growth and development may occur due to low intake
of DHA and its precursor EPA (Quinn et al., 2010b). DHA is also re-
commended to treat cardiovascular disease (CVD) risk factors such as
hypercholesterolemia, hypertriglyceridemia, and hypertension (Mori
et al., 2000a,b). Higher intake of DHA is usually recommended to
prevent CVD. EPA is mostly involved in cell signalling, whereas DHA is
mainly used for cell membrane structure and function (Bradbury, 2011;
Innis, 2008). However, recently several studies demonstrated the sig-
nalling pathways of DHA metabolites in the brain. A signicant number
of reviews are available on DHA and human brain (Bradbury, 2011;
Brenna and Carlson, 2014;Salem and Eggersdorfer, 2015;Sun et al.,
2018). This review describes the roles of DHA and its metabolites in the
structure and function of the human brain.
2. DHA uptake and metabolism in human
DHA is mostly deposited in the brain and retina, whereas its dis-
tribution in other tissues such as heart, liver, skeletal muscle, adipose
tissue, blood cell is low. The most signicant n-3 fatty acid present in
the brain is DHA, whereas EPA and ALA are present in very small
amounts. DHA constitutes over 90% of the n-3 PUFAs in the brain and
constitutes 10%20% of its total lipids (Brenna and Carlson, 2014).
DHA is especially found in the grey matter (Suzuki et al., 1997). In a
cellular context, DHA is esteried into the cell membrane phospholipids
mostly in phosphatidylethanolamine and phosphatidylserine and other
complex lipids (Calder, 2016). Following insertion into the cell mem-
brane, DHA interacts with cholesterol that inuences the membrane
phospholipid width by packing constraints and conformation of ad-
jacent phospholipid acyl chains (Sherratt and Mason, 2018). Physical
nature of DHA increases electron density in the phospholipid head
group region within the cell membrane, which attributes rapid con-
formational changes. Owing to the unique structure, DHA is capable of
providing a wide range of cell membrane structure and functions. Thus,
DHA aects dierent biophysical characteristics and physiological
processes such as membrane uidity, lipid raft function, neuro-
transmitter release, membrane receptors, gene expression, signaling
pathways, myelination, inammation, and cell growth and dier-
entiation (Duttaroy, 2016;OBrien and Sampson, 1965;Sun et al.,
2018;Suzuki et al., 1997). Depending on the maternal supply of ALA,
EPA or DHA, DHA accumulates in the fetal brain during the last period
of pregnancy. The brains frontal lobes are more responsive to DHA
supply in adolescent and older adults for executive and higher-order
cognitive activities (Goustard-Langelier et al., 1999).
EPA plays a dominant role in inhibiting delta-5-desaturase enzyme-
mediated production of the arachidonic acid,20:4n-6(AA). Therefore,
the AA derived pro-inammatory eicosanoids (prostaglandins, throm-
boxanes, leukotrienes) are inhibited by EPA intake in the diet. Also,
EPA competes with AA for phospholipase A
enzyme. These are unique
roles of EPA whereas DHA neither ts the catalytic site of delta-5-de-
saturase enzyme nor competes with AA for phospholipase A
due to its massive spatial structure. Unlike DHA, EPA level is not high
enough in the brain to contribute to neurological function. EPA is re-
ported to be rapidly oxidized in the brain (Chen et al., 2009).
While EPA inhibits the delta-5-desaturase enzyme that directly in-
hibits AA, DHA inhibits another role-playing enzyme delta-6-desaturase
enzyme that involves in LA metabolism (Sato et al., 2001). Due to more
massive spatial structure, DHA sweeps out a higher volume of uid in
the membrane than EPA which increases in membrane uidity for
critical synaptic vesicles and the retina to transmit signals from the
surface of the membrane to the interior of the nerve cells. DHA may also
involve in the breakup of lipid rafts in membranes due to its continuous
sweeping motion (Chapkin et al., 2008). As a result, cancer cells cannot
survive, and inammatory cytokines struggle to initiate signaling re-
sponses (Li et al., 2005). The spatial characteristics of DHA cause an
increase in the LDL particle sizes comparatively, which reduces the
entry of LDL particles into arterial muscle cells to develop athero-
sclerosis lesions (Mori et al., 2000a).
3. Dietary and metabolic sources of DHA and its worldwide
DHA and EPA are present together ubiquitously in marine mammals
and plant plankton, whereas all terrestrial plants contain ALA. DHA and
EPA are present in marine sources as triacylglycerols and phospholi-
pids. Usually, 100 g of cooked salmon sh contains 5001500 mg DHA.
Caviar, anchovies, mackerel, and herring are the other high sources of
DHA (Agriculture, 2005). Beef, lamb, pork, and chicken contain around
0.02 gm of DHA per 100 gm of meat (Calder, 2016). Although DHA is
mainly obtained from marine sh sources, nowadays, DHA is com-
mercially manufactured from microalgal sources such as Crypthecodi-
nium cohnii and Schizochytrium (Ulven and Holven, 2015). The meta-
bolic biosynthesis of DHA via a series of elongation, desaturation, and
beta-oxidation reactions from EPA is known as Sprechers Shunt
(Burdge et al., 2002;Burdge and Wootton, 2002). Maternal DHA sup-
plementation can contribute to brain and visual development and
function of the fetus and the infant. Maternal breast milk also contains
DHA around 0.32% of total fatty acid (Calder, 2016). N-3 LC-PUFA
dietary supplements are widely available, usually in the triacylglycerol,
non-esteried fatty acid, and ethyl ester forms. The sh oil supplements
are reported not only have n-3 LCPUFA contents well below those
claimed by labels but are also considerably oxidized(Albert et al.,
2015); however, the associated health implications of consuming oxi-
dized LCPUFAs are unclear(Myhrstad et al., 2016)
The human body converts ALA to EPA and DHA via desaturases and
elongases pathways. ALA and LA compete for the same desaturase and
elongase in order to form their respective LCPUFA metabolites (Chilton
et al., 2014;Duttaroy, 2009). Low levels of vitamin B6, magnesium,
zinc and ageing reduce the delta 6 desaturase activity. The activity of
delta-6-desaturase is also blocked by trans fats, present in hydrogenated
oils, fast foods, and many packaged foods. The delta 6 desaturase ac-
tivity is decreased in chronic alcoholism and in diabetes. Delta 5 de-
saturase is inhibited by deciencies of vitamin C, niacin and zinc.
Higher intakes of LA can dominate these enzymes, especially the delta 6
desaturase enzyme (FADS2); thus biosynthesis of EPA and DHA from
ALA is reduced. So, consumption of the higher amount of ALA can in-
crease DHA level to some extent; however, this may not increase plasma
DHA in humans suciently (Neet al., 2010;Plourde and Cunnane,
2008). Fig. 1 shows the conversion of dietary ALA to EPA and DHA. In
order to increase the DHA level in the body, dietary supplementation of
DHA is the most preferred strategy (Cunnane et al., 2013). The synth-
esis of DHA from ALA by elevating levels of enzymes such as FADS2 and
elongase 2 by curcumin is promising. Interestingly, curcumin also en-
hances DHA absorption (Wu et al., 2015). Curcumin is widely con-
sumed as a cooking spice in Indian sub-continent; therefore, the low
intake of DHA in this population may be compensated by the curcumin
intake. Another nutraceutical, quercetin enhanced the anti-in-
ammatory eects of DHA on LPS-stimulated inammatory response in
microglial cells (Sun et al., 2019). These studies indicate that the cer-
tain phytochemicals may enhance the synthesis, bioavailability and
functionalities of DHA; however, further work is required to promote
the role of these phytochemicals in DHA mediated human health ef-
Retro-conversion of DHA to EPA occurs in the peroxisomes via β-
oxidation to remove the double bond at position 4. Retro-conversion of
DHA is more common in non-neural cells than neural cells (Park et al.,
2016). However, recently it was shown that increased plasma level of
EPA in human following DHA supplementation did not occur via retro-
conversion rather a result of slowed metabolism and/or accumulation
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
of plasma EPA (Metherel et al., 2019). During the last 30 years or so,
the increasing incidence of several metabolic diseases are thought to be
due to the results of high dietary intake of n-6 fatty acid containing
foods and oils compared with n-3 fatty acids, thus increased the ratio of
n-6:n-3 fatty acids (20:1) intake to a much higher level than the re-
commended ratio for optimal health benets (Simopoulos, 2016).
DHA intake among developed countries varies a lot. DHA intake is
the highest among the people in Iceland (793.4 mg/day). Even in the
USA, daily DHA intake is around 3.5 times lower than that of Iceland.
Among the Scandinavian countries, Danish people consume the highest
level of DHA (232.3 mg/day). The highest and lowest DHA consump-
tion levels in developing countries by the people of Maldives
(1409.3 mg/day) and Ethiopia (7.01 mg/day) respectively. Estimated
dietary intake indicate that the people from India consume only
52.1 mg DHA/day, while people from Bangladesh consume 167 mg
DHA/day through diet. Pakistanis (24 mg/day) and Nepalese (23.2 mg/
day) consume the lowest level of DHA among all South-Asian countries
(Forsyth et al., 2016). Overall, the daily intake of DHA as a per cent of
daily total energy intake (% energy) from food sources is highest in
Japan (0.152%) followed by China (0.090%), USA and Canada
(0.055%). The people from Oceania and Europe continents consume
0.052% DHA of total energy intake. However, these data had several
limitations including the fact that the data did not directly measure
food consumption but instead reected the food supply in a certain
country and might not accurately reect the real intake of DHA. DHA
consumption is lowest in low-income countries (Forsyth et al., 2016).
The countries having access to coastal areas consume a greater amount
of seafood, and therefore, dietary intake of DHA in these countries is
quite higher than other countries comparatively. N-3 PUFA intake of
0.52.0% of total energy is recommended for adults. Dietary intakes of
0.1-0.18% DHA of total energy for infants above six months old and
1012 mg of DHA/Kg body weight for infants aged up to six months are
recommended (WHO and FAO, 2008). Pregnant or breastfeeding mo-
thers are advised to consume 200 mg of DHA, or 300900 mg of com-
bined EPA and DHA per person per day. Vegetarians and vegans can
take microalgae supplements that contain DHA (Davis and Kris-
Etherton, 2003;Yurko-Mauro et al., 2010). The European Food Safety
Authority (EFSA) recommended a maximum dose of 5 g/day of
EPA + DHA as safe (EFSAReport, 2019).
4. DHA and its impact on the structure and function of the brain
As a crucial structural membrane component of the brain, DHA is
present in the cerebral cortex, synaptic membrane regions, retinal mi-
tochondria, and photoreceptors. Brain and retina tissues contain around
40% and 60% DHA of total PUFAs, respectively. DHA is present in high
amounts in retinal photoreceptors and is therefore essential for visual
function(Liu et al., 2011). Animal studies and human observational
studies have suggested that there is an inverse relationship between
dietary intake of n-3 LCPUFAs and the risk of developing agerelated
macular degeneration. The data from intervention trials have been
mixed, although the delayed progression of an intermediate type of
agerelated macular degeneration was reported earlier (Huang et al.,
2008). The later studies did not nd any positive eect on the age-
related macular after supplementation with n-3 LCPUFAs (Souied et al.,
2015;Wu et al., 2017). The X-linked retinitis pigmentosa was shown to
be improved with DHA supplementation (Homan et al., 2004). The
recent clinical trial did not observe such improvement for X-linked re-
tinitis pigmentosa(Homan et al., 2014). However, some positive ef-
fects, such as the reduced elevation in nal dark-adapted thresholds and
slowed loss of the visual eld sensitivity, were observed (Homan et al.,
Neuronal cell membranes contain approximately 50% DHA (Calder,
2016;Singh, 2005). DHA contributes around 15% of the total fatty acid
composition in the adult prefrontal cortex. DHA is important for hip-
pocampal and cortical neurogenesis, neuronal migration, and out-
growth (Calderon and Kim, 2004;Cao et al., 2005;Kawakita et al.,
2006). DHA suppresses cell death by promoting cell-cycle exit in neuro-
progenitor cells (Insua et al., 2003;Kawakita et al., 2006). Along with
other fatty acids, DHA has a signicant role in monoaminergic and
cholinergic systems during brain development (Aïd et al., 2003;Chalon,
2006;Innis, 1991). Prenatal DHA supply has a long term eect on
serotonergic and dopaminergic neurotransmission (Anderson et al.,
2005;Chalon, 2006) indicating the importance of DHA as a nutrient in
early brain development. DHA inuences gene expression, neuro-
transmission, and oxidative stress (Innis, 2018). DHA is an essential
factor for neurogenesis, phospholipid synthesis, and turnover (Coti
Bertrand et al., 2006;Kawakita et al., 2006;Salem et al., 2001).
The brain is atrophied in dierent neurodegenerative diseases.
Brain atrophy is also associated with age and cognitive degradation.
Various studies showed that DHA could improve learning and memory,
along with neuronal loss reduction (Weiser et al., 2016). DHA accu-
mulates during intrauterine fetal brain growth and maintains its levels
lifelong (Carver et al., 2001). DHA accumulation in the fetal brain is
highest during the third trimester of pregnancy. DHA incorporation into
brain membrane in early life solely depends on its supply via the pla-
centa, breastfeeding, and endogenous LCPUFAs production (Duttaroy,
2016;Innis, 2008;Lauritzen et al., 2016). DHA has a signicant role in
both brain and retinal development (Authority, 2011;Lauritzen et al.,
2016). Since the brain has a critical developmental window in utero as
Fig. 1. DHA synthesis in the body.
The plant source provides us ALA is converted
to EPA and DHA. The desaturations and elon-
gations occur in the endoplasmic reticulum,
and the β-oxidation occurs in the peroxisome,
to where 24-carbon PUFA are transferred. The
animal source provides us with EPA and DHA
without the need of conversion process. The
enzyme delta 6 desaturase is required to begin
the conversion of ALA.
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
well as during the postnatal life, therefore, any perturbations such as
nutritional and environmental or postnatal nutrition would sig-
nicantly aect brain development. During critical periods of devel-
opment, any perturbation leads to profound and potentially irreversible
defects of brain maturation. A signicant linear relationship between
maternal DHA level and umbilical cord plasma phospholipid contents
are observed (Calder, 2016). Optimal placental growth and develop-
ment are crucial for the eective exchange of nutrients and waste
products between the mother and the fetus (Basak et al., 2013). The
growing fetus mostly depends on the placental supply of maternal DHA
due to its limited DHA synthetic capacity (Duttaroy, 2000). Aberrant
placental development with a deranged vasculature may inuence fetal
development and survival (Duttaroy, 2016). Recent studies suggested
that DHA has a role in early placentation processes along with the brain
and retinal development during the last trimester of pregnancy (Basak
et al., 2013;Duttaroy, 2000;Johnsen et al., 2011). Preferential transfer
of maternal DHA to the fetus during the last trimester of pregnancy was
suggested to be performed by the high-anity placental plasma mem-
brane fatty acid-binding protein (p-FABPpm) (Duttaroy, 2009).
Intracellular DHA is transported by FABPs (please see details on
FABP in the next section). DHA is the ligand for peroxisome pro-
liferator-activated receptor gamma (PPAR-γ), which is expressed in the
embryonic mouse brain and neural stem cells. The critical early brain
development regulator, PPAR-γheterodimerizes with the retinoid X
receptor (RXR) and regulates the transcription of target genes (Wada
et al., 2006). DHA is one of the key ligands for brain RXR (Lengqvist
et al., 2004). Along with retinoic acid receptor, RXR plays an important
role in embryonic neurogenesis, neuronal plasticity, and catecholami-
nergic neuron dierentiation. RXR is highly expressed in the hippo-
campus (Lengqvist et al., 2004;Rioux and Arnold, 2005). As a free
radical scavenger, DHA protects the developing brain from peroxidative
damages of lipid and protein (Cao et al., 2004;Green et al., 2001;
Okada et al., 1996).
5. Fatty acid transport and metabolism in the human brain
It is generally assumed that the transport of fatty acids to the tissues
occurs in the form of the non-esteried pool of fatty acids (FFAs) bound
to serum albumin. The plasma FFAs is transferred across the cell via
fatty acid membrane transporters (FAT, FABPpm. FATP) and cyto-
plasmic fatty acid-binding proteins (FABPs) (Duttaroy, 2009). Fig. 2
summarises the putative roles of fatty acid-binding/transport proteins
in the uptake of free fatty acids. Recent studies showed that the
mammalian brain uniquely takes up DHA in the form of lysopho-
sphatidylcholine (LPC-DHA) (Chan et al., 2018). LPC-DHA uptake is
mediated by the major facilitator superfamily domain-containing pro-
tein 2 (Mfsd2 or Mfsd2a) present at the blood-brain barrier (Nguyen
et al., 2014). Therefore it may be necessary to increase the plasma level
of LPC-DHA for ecient enrichment of brain DHA in human, however
further work is required for conrmation. An essential requirement
common to both prenatal and postnatal brain development is the bio-
synthesis of a huge amount of membrane phospholipid, the origin of
which was believed to be exclusively derived from de novo biosynthesis
within cells of the brain, and acquisition of essential fatty acids from the
periphery into the developing brain. A major function of DHA during
brain development is to regulate SREBP-1 and SREBP-2 activity re-
sulting in major changes in phospholipid saturation(Huang et al.,
2017). FABP is thought to play a crucial role in the cytoplasmic fatty
acid transfer and thus help fatty acids aect gene expression and
synthesis of other metabolites. There are two types of FABPs available
in the brain: (1) B-FABP, which is found in ventricular germinal and
glial cells in the embryonic brain and in the astrocytes of developing
and adult brains and (2) H-FABP, which is only available in adult brains
(Owada et al., 2006;Veerkamp and Zimmerman, 2001). DHA has a
preference for binding with B-FABP that may be necessary for early
neurogenesis or neuronal migration (Owada et al., 2006).
Fatty acid metabolism is one of the vital steps for energy require-
ment in the brain. Brain gets 20% of total energy from β-oxidation of
fatty acid in mitochondria of astrocytes. In the pre-oxidation step, fatty
acids are initially converted to fatty acyl-CoA by acyl-CoA synthases.
Besides mitochondria, peroxisome also plays a signicant role in fatty
acid metabolism. Peroxisome proliferator-activated receptor α(PPAR-
α) stimulates the expression of catabolic enzymes, such as the CPT fa-
mily, and acyl-CoA dehydrogenases in low energy status (Tracey et al.,
2018). Through the β-oxidation, very long and branched-chain fatty
acids are oxidized to shorten them. Also, α-oxidation clears a single
carbon from fatty acids that are incapable of typical β-oxidation in
peroxisome (Tracey et al., 2018). The peroxisomal β-oxidation is unable
to breakdown the full fatty acids, while mitochondria degrade the fatty
acids completely via the tricarboxylic acid pathway (Tracey et al.,
2018). However, for energy production, utilization of fatty acids is in-
creased signicantly during fasting or extreme exertion which may
damage the brain due to reactive oxygen species, specically in the
form of superoxide (Tracey et al., 2018).
Another important pathway for the utilization of fatty acids in brain
astrocytes is the ketogenesis pathway. Ketone bodies may form from
fatty acid-derived acetyl-CoA in the hypoglycemic condition. In suitable
condition, these ketone bodies are lysed again into acetyl-CoA, which
again enter into the tricarboxylic acid cycle (Tracey et al., 2018).
6. Roles of DHA and its metabolites in brain function
As an integral component of cell membrane phospholipid, DHA
contributes to maintaining membrane uidity and lipid raft assembly
and other membrane functions. DHA inuences electrical, chemical,
hormonal, or antigenic signals of the cells. One study demonstrated that
higher signal transduction mediated by two DHA molecules than no or
one DHA molecule along with other highly unsaturated fatty acids in
the phospholipid bilayer (Calder, 2016). DHA acts via cell membrane
surface and intracellular receptors. DHA promotes membrane-asso-
ciated G-protein-coupled receptor (GPR)120 mediated gene activation
to promote anti-inammatory conditions (Oh et al., 2014). DHA also
activates PPARs and upregulates PPAR targeted genes to increase in-
sulin sensitivity, reduce plasma triglyceride level and inammation
(Calder, 2016). Dietary intervention plays a signicant role to maintain
healthy brain function, which prevents stress, depression, and brain
degenerative disorders (McEwen, 2010;Sun et al., 2018). The bene-
cial eects of DHA are mediated by the fatty acid itself (PPAR ligand)
as well as by its bioactive metabolites. DHA and its metabolites have a
wide range of actions at dierent levels and sites (Diep et al., 2000;
Zúñiga et al., 2011). The DHA metabolites have a wide range of actions
at dierent levels and sites. Table 1 summarizes various functions of
DHA metabolites. Bioactive DHA-derived specialized pro-resolving
mediators (SPMs), DHA epoxides, electrophilic oxo-derivatives (EFOX)
of DHA, neuroprostanes, ethanolamines, acylglycerols, docosahex-
aenoyl amides of amino acids or neurotransmitters, and branched DHA
esters of hydroxy fatty acids are the metabolic end products of DHA
(Anderson and Taylor, 2012;Robertson et al., 2013). Also, epox-
ydocosapentaenoic acids (EDPs) and 22-hydroxydocosahexaenoic acids
(22-HDoHEs) are the metabolized from DHA (Kuda, 2017;Westphal
et al., 2011). 5-, 12- and 15-lipoxygenases (LOX), COX-2 and cyto-
chrome P450 (CYP) are the responsible enzymes for DHA metabolism.
Table 2 summarizes the enzymes responsible for DHA metabolism. As
most exigent by-products of DHA, resolvins are formed by either LOX15
or CYP or aspirin-treated COX-2 stimulation (Fig. 3)(Duvall and Levy,
2016;Sun et al., 2018). Although the LOX15 treated formed resolvins
are homologous to CYP, or aspirin-treated formed resolvins (Duvall and
Levy, 2016). As the potential inammation resolution mediators, re-
solvins act through a dierent GPR (Duvall and Levy, 2016;Serhan,
The neuroprotectors, resolvin D1, and aspirin-triggered resolvin D1
improve brain functions and impair neuronal death by downregulating
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
NF-kB, TLR4, CD200, and IL6R (Bisicchia et al., 2018;Recchiuti et al.,
2010). They induce remote functional recovery after brain damage
(Bisicchia et al., 2018). Resolvin D2 and aspirin-triggered resolvin D2
protect from cerebral ischemic injury through ERK1/2 phosphorylation
followed by stimulation of nNOS or eNOS to inhibit programmed
neuronal cell death and increase zonula occludens-1 for the main-
tenance of blood-brain barrier integrity (Zuo et al., 2018). Resolvin D3,
resolvin D5, aspirin-triggered resolvin D3, and aspirin-triggered re-
solvin D5 halt neuroinammatory process (Dalli et al., 2013;Hong
et al., 2005). However, the functions of other resolvins are still not
Table 3 shows the DHA-derived resolvins and their receptors with
Macrophage derived anti-inammatory pro-resolving mediator;
maresins are biosynthesized from DHA in response to inammation,
healing, and regeneration process (Ariel and Serhan, 2012;Stables
et al., 2011;Zhang and Spite, 2012). Maresin 1(MaR1) is the leading
subtype of maresins. Along with the reduction of LTB
MaR1 stimulates macrophagic phagocytosis and eerocytosis at the
inammatory site (Serhan et al., 2015b,2012;Serhan et al., 2008).
MaR1 regulates stem cell dierentiation to accelerate tissue repair
along with an analgesic role via TRPV1-mediated responses blockage
(Serhan et al., 2012;Yanes et al., 2010). MaR1 plays a role in the im-
provement of neurocognitive functions by regulating macrophage in-
ltration, NF-κB signaling, oxidative stress, and after cytokine release
Maresin 1 attenuates neuroinammation in a mouse model of perio-
perative neurocognitive disorders (Yang et al., 2019). Also, MaR1 has
shown signicant improvement of locomotive function in a post-spinal
cord injury model (Francos-Quijorna et al., 2017).
Neuroprotectin D1(NPD1) is one of the DHA derived SPMs, improve
brain cell survival, and repair in ageing and neurodegenerative diseases
(Bazan et al., 2011). Like MaR1, NPD1 also possesses anti-inammatory
and neuroprotective activity (Balas and Durand, 2016). However, NPD1
has anti-apoptotic activity, which makes it unique from MaR1 (Ariel
Fig. 2. Schematic representation of fatty acid transport mediated by fatty acid binding/transport proteins.
The family of FATPs, FAT, FABPpm and MFSD2A facilitate the uptake of fatty acids into tissues. However, the FATPs also possess ACSL activity and facilitate the ux
of fatty acids across membranes secondary to metabolic eects. After uptake, fatty acids are bound by cytoplasmic FABPs. Fatty acids can undergo a number of
metabolic fates. Fatty acid transport proteins modulate cognition by inuencing brain fatty acid transport and therefore by modulating the supply of the needed fatty
acids to the brain.
Table 1
Functions of DHA metabolites.
Types of metabolites Name of metabolites Eects
Oxygenated metabolites Maresins Resolution of inammation, wound healing, analgesic actions
Protectins Resolution of inammation, neuroprotection
Resolvins Resolution of inammation and wound healing
Electrophilic oxo-derivatives (EFOX) of DHA Anti-inammatory, anti-proliferative eects
Epoxides Anti-hypertensive, analgesic actions
Neuroprostanes Cardioprotection, wound healing
DHA conjugates Ethanolamines and glycerol esters Neural development, immunomodulation, metabolic eects
Branched fatty acid esters of hydroxy fatty acids (FAHFA) Immunomodulation, resolution of inammation
N-acyl amides Metabolic regulation, neuroprotection, neurotransmission
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
et al., 2005;Serhan et al., 2015b). In response to neuroinammation,
NPD1 is produced from endogenous DHA in retina and brain (Bazan,
2005;Calandria et al., 2009). Besides antiviral protection, NPD1 helps
in neurocognitive functions (García-Sastre, 2013;Morita et al., 2013;
Zhao et al., 2011). NDP1 can repress inammation, oxidative stress,
and cell apoptosis induced by Ab 42 and promote neuronal survival.
NDP1 may prevent Alzheimer's disease progression through upregu-
lating PPARγ, amyloid precursor protein-α, and downregulating β-
amyloid precursor protein. Thus, the amyloid-βpeptide is reduced in
neuronal tissue (Zhao et al., 2011).
Anti-inammatory signaling properties of EFOX and neuroprostanes
are benecial for dierent neuroinammatory disorders in association
with Parkinsons disease, and Alzheimers disease (Dyall, 2015;Gladine
et al., 2014;Groeger et al., 2010). On the other hand, docosahexaenoyl
ethanolamide improves energy homoeostasis in association with mood,
pain modulation, anti-inammation, hunger, and glucose uptake in the
brain through the endocannabinoid system (De Petrocellis et al., 1999;
Kim et al., 2014;Piazza et al., 2007;Soderstrom, 2004;Valenti et al.,
2005;Watanabe et al., 2003).
DHA glyceryl ester controls food intake and neuroinammation in
the brain in the same fashion as docosahexaenoyl ethanolamide by
using the endocannabinoid system (DAddario et al., 2014;Masoodi
et al., 2015). As an integral part of brain structure, the endocannabinoid
system has a signicant role in memory, cognition, and pain perception
(Wagner and Alger, 1996;Wilson and Nicoll, 2002). DHA conjugates
reduce neuroinammation and cause neurogenesis by acting on can-
nabinoid receptors (Calder, 2013;Lu and MacKie, 2016).
Stress-induced hormone production via hypothalamus-pituitary-
adrenal (HPA) axis pathways can be regulated and modulated by nu-
tritional approaches (Lupien et al., 2009;Ranabir and Reetu, 2011).
The lipid is an integrated part of the brain, so fatty acid status should
have a relationship with stress (Laugero et al., 2011;OBrien and
Sampson, 1965). Adequate dietary DHA supplementation lowers HPA
activation, corticosterone peak, and stress-induced weight loss (Chen
and Su, 2013;Hennebelle et al., 2012). Not only to alleviate short-term
stress, but DHA also has a signicant role in brain development, which
prevents anxiety and stress in later life (Robertson et al., 2013;Song
et al., 2008). Although, due to some conicting precedents for asso-
ciation with PUFA supplementation and cognitive development, it has
become more critical to determine optimum DHA doses for eective
neurodevelopment at dierent ages (Qawasmi et al., 2012;Simmer
et al., 2011;Smithers et al., 2008). Stress stimulated TNF-alfa, and IFN-
γproduction, lipopolysaccharide (LPS) stimulated IL-6 production are
reduced by a signicantly higher level of DHA supplementation
Table 2
Enzymes responsible for DHA metabolism.
Enzymes Mode of action
5-, 12- and 15-lipoxygenases converts DHA to DHA hydroperoxides (HpDHA), which are further metabolized by hydrolases, and several members of the CYP superfamily
(Serhan et al., 2015b;Spite et al., 2014).
Cyclooxygenase-2 converts DHAinto resolvins when triggered with aspirin, EFOX (Groeger et al., 2010;Lima-Garcia et al., 2011).
CYP Epoxygenases such as CYP2C, CYP2J produce EDPs from DHA, while ω/(ω-1)-hydroxylases such as CYP4A, CYP4F produce 22-HDoHEs (Westphal
et al., 2011).
Fig. 3. DHA metabolites formation and function in the brain.
DHA is converted into maresin 1(MaR1), neuroprotectin D1(NPD1) and resolvins by human 12-LOX, 15-LOX and CYP or aspirin-treated COX-2 enzymatically. These
metabolites have multiple functions in the brain, which have been mentioned in the upper and lower boxes. DHA is metabolised by P450 system, cyclooxygenase, and
lipoxygenase enzymes under dierent metabolic conditions.
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
(Kiecolt-Glaser et al., 2011;Lucas et al., 2009;Maes et al., 2000;
Robertson et al., 2013).
Though stress and anxiety have a close relationship with depression,
DHA is suggested to be an important nutrient for preventing and
treating depression (Murray and Lopez, 1996;Robertson et al., 2013).
DHA has shown some benecial eects in the treatment of various
psychiatric disorders, e.g., schizophrenia, unipolar and bipolar mood
disorders, anxiety disorders, obsessive-compulsive disorder, ADHD,
autism, aggression, hostility and impulsivity, borderline personality
disorder, substance abuse and anorexia nervosa (Bozzatello et al., 2016;
Sun et al., 2018). During the last decades several trials using n-3
LCPUFAs in mental diseases were performed. However, the ndings of
most of the trials are controversial and inconclusive(Pusceddu et al.,
2016;Sun et al., 2018).
There is evidence that consumption of n-3 fatty acids containing
shes reduce depression (Hibbeln, 1998). However, the studies have
shown that EPA is more potent to treat depression than DHA (Bourre,
2005;Marangell et al., 2003;Peet and Horrobin, 2002). Lower pro-
inammatory plasma IL-6 level and higher EPA/AA ratio have been
observed in PUFA treated depressed patients (Lin and Su, 2007).
Higher consumption of marine sh improves cognitive function
(Van Gelder et al., 2007). DHA has a signicant role in the reduction of
dementia risk (Schaefer et al., 2006). Neuroinammation can be dam-
pened by DHA supplementation in the pathogenesis of Alzheimers
disease (Kinney et al., 2018;Trépanier et al., 2016). DHA derived anti-
inammatory eicosanoids, neuroprotectins prevent Alzheimer's disease
pathogenesis (Lukiw et al., 2005). DHA regulates Alzheimer's disease-
related processes such as cholesterol and apolipoprotein E (APOE)
along with lipid raft assembly alteration and cell signalling regulation
(Boudrault et al., 2009;Hashimoto et al., 2005). Neuronal protection
against cytotoxicity, inhibition of nitrogen oxide production, calcium
inux, activation of antioxidant enzymes (glutathione peroxidase and
glutathione reductase) and reduction of apoptosis are the signicant
molecular functions of DHA (Seidl et al., 2014). The second most pre-
valent neurodegenerative disease, Parkinsonsdisease is suggested to be
prevented by the neuroprotective role of DHA (Seidl et al., 2014). At-
tention decit hyperactivity disorder (ADHD) is another common
neurodevelopmental disorder among school-aged children that leads to
severe problems in social behavior. Studies showed evidence for the
successful treatment of a mild form of ADHD symptoms with DHA
supplementation (Kiliaan and Königs, 2016). Several reviews on DHA
supplementation in ADHD were published in recent years(Ramalho
et al., 2018;Sun et al., 2018). Despite the heterogeneity of the studies,
DHA may contribute to improvements in the capacity of reading,
learning, nonverbal cognitive development, perceptive visual capacity
and executive function of ADHD children. Future in depth large-scale,
well-designed randomized clinical trials are required to achieve
evidence for clinical recommendations.
Bipolar disorder of the brain is characterized by periods of depres-
sion and mania. DHA improves depressive symptoms of bipolar dis-
order by increasing N-acetyl-aspartate levels in the brain, but it has no
signicant eects on the protection of mania (Bozzatello et al., 2016).
Intelligence quotient in children and cognitive function in the ageing
brain are improved by DHA supplementation (Lauritzen et al., 2016;
Weiser et al., 2016). Sun et al. (Sun et al., 2018)recently reviewed the
mechanistic relationships of brain DHA with dierent mental disorders,
including autism. Interestingly the studies have been reported that EPA
in association with DHA improves outcome in cognitive function than
DHA alone. DHA can be divided into two dierent types based on their
properties in brain function: lipid-bound DHA in membrane bilayer and
unesteried DHA (Innis, 2018). Lipid-bound DHA inuences lipid
rafting, signal transduction, and neurotransmission (Chalon, 2006;
Grosseld et al., 2006;Stillwell et al., 2005). On the other hand, reg-
ulation of gene expression and ion channel activities are related to
unesteried DHA properties (Bazan, 2006;Kitajka et al., 2002;
Vreugdenhil et al., 2002). DHA also inhibits cell migration, growth
arrest and apoptosis of brain tumor cells via activation of PPAR-γin the
nucleus (Mita et al., 2010).
7. DHA deciency and human brain function
As an integral component of brain structure, fatty acids play a sig-
nicant role in healthy brain function. Dierent diseases/disorders,
e.g., Alzheimer's disease, Parkinsons disease, Huntingtons disease,
schizophrenia, mood disorders, are linked due to altered membrane
fatty acid composition and their signalling in disease progression
(Bazinet and Layé, 2014;Shamim et al., 2018). The encephalopathy
Reye syndromeis causally associated with altered fatty acid oxidation
(Orlowski, 1999). A rare congenital peroxisome biogenesis disorder
called by "Zellweger syndrome," is linked with abnormal fatty acid
accumulation that impairs brain development (Crane, 2014). DHA de-
ciency is linked with depressive disorder, bipolar disorder
(McNamara, 2010;McNamara et al., 2007).
The studies on pregnant women showed that DHA deciency might
lead to poor language skill among children (Mulder et al., 2014). Even
autistic spectrum disorder or ADHD among teenagers is related to DHA
deciency (Bos et al., 2015;Parellada et al., 2017). Due to DHA de-
ciency, neurocognitive functional insuciency in young adults or
loneliness related memory problems in middle age has been observed
(Bauer et al., 2014;Jaremka et al., 2014). DHA deciency in the third
trimester signicantly aects brain development (Smith and Rouse,
Table 3
DHA-derived resolvins and their receptors with functions.
DHA-derived Resolvins Receptors Functions
Resolvin D1 Stimulates GPR32 and FPR2 (Serhan et al., 2015a)
Inhibits TRPV3, TRPV4 and TRPA1 (Serhan et al., 2015a)
Anti-inammatory (Qu et al., 2015)
Analgesic (Farooqui, 2012)
Resolvin D2 Stimulates GPR32, GRP18 and FPR2 (Lim et al., 2015;Shinohara and Serhan, 2016)
Inhibits TRPV1 and TRPA1 (Lim et al., 2015;Shinohara and Serhan, 2016)
Anti-inammatory (Qu et al., 2015)
Analgesic (Klein et al., 2014)
Resolvin D3 Stimulates GPR32 (Serhan et al., 2015a)Anti-inammatory (Qu et al., 2015)
Resolvin D4 Unknown Unknown
Resolvin D5 Stimulates GPR32 Anti-inammatory (Qu et al., 2015)
Resolvin D6 Unknown Unknown
Aspirin triggered resolvin D1 Stimulates GPR32 and FPR2 (Lim et al., 2015;Serhan et al., 2015a) Inhibits TRPV3, TRPV4 and
TNFR (Lim et al., 2015;Serhan et al., 2015a)
Anti-inammatory (Qu et al., 2015)
Analgesic (Farooqui, 2012)
Aspirin triggered resolvin D2 Unknown Unknown
Aspirin triggered resolvin D3 Stimulates GPR32 (Serhan et al., 2015a)Anti-inammatory (Qu et al., 2015)
Aspirin triggered resolvin D4 Unknown Unknown
Aspirin triggered resolvin D5 Unknown Unknown
Aspirin triggered resolvin D6 Unknown Unknown
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
8. Clinical trials of DHA supplementation and brain function
N-3 LCPUFAs supplementation is recommended worldwide for feto-
maternal and maternal-childhood growth and development, and cog-
nitive function of the child(Carlson et al., 2013;Julvez et al., 2016;
Koletzko et al., 2007;Parra-Cabrera et al., 2011). DHA supplementation
improved pregnancy outcome, gestation, reduction in early preterm
and very low birth weight, childhood visual and psychomotor devel-
opment (Carlson et al., 2013;Shulkin et al., 2018).
Several clinical studies were reported on n-3 LCPUFAs and mental
disorders. Some of these clinical trials and their health outcomes are
presented in Table 4. Most of the clinical studies did not show any
signicant eects of DHA supplementation (Sun et al., 2018). Dier-
ences in methodologies, the sample size, dietary habit, selection cri-
teria, age, choice and dosage of LCPUFAs (EPA, or DHA, or a combi-
nation of EPA + DHA) and the duration of the intervention are mostl
possibly responsible for inconclusive results(Sun et al., 2018).
9. Conclusions
The optimal structure and function of the brain are critical for
quality of life, productivity and individual growth. DHA and its meta-
bolites inuence the brains development, structure and functions,
signaling pathways, receptor function, and enzyme activities. All these
functionalities are critical for optimum brain physiology throughout the
lifespan. In order to achieve these functionalities, sustained supply of
DHA is required well before conception, during the gestation period,
adolescence, adulthood and adult life. Therefore, maintaining optimal
levels of DHA in the brain are likely to be required throughout the
lifespan by obtaining preformed DHA via dietary or supplementation.
Several studies suggest that the consumption of DHA leads to many
inherent positive physiological and behavioral eects, however further
clinical trials are required to assess dierent clinical outcomes, in-
cluding mental health status and quality of life.
Declaration of Competing Interest
The authors declare no conict of interest.
This study was supported by the Throne Holst Foundation and the
Faculty of Medicine, University of Oslo, Norway.
Agriculture, U.D., 2005. EPA and DHA Content of Fish Species. Appendix G2.
Aïd, S., Vancassel, S., Poumès-Ballihaut, C., Chalon, S., Guesnet, P., Lavialle, M., 2003.
Eect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat
hippocampus. J. Lipid Res. 44, 15451551.
Albert, B.B., Derraik, J.G., Cameron-Smith, D., Hofman, P.L., Tumanov, S., Villas-Boas,
S.G., et al., 2015. Fish oil supplements in New Zealand are highly oxidised and do not
meet label content of n-3 PUFA. Sci. Rep. 5, 7928.
Anderson, E., Taylor, D., 2012. Stressing the heart of the matter: re-thinking the me-
chanisms underlying therapeutic eects of n-3 polyunsaturated fatty acids. F1000
Med. Rep. 4, 13.
Anderson, G.J., Neuringer, M., Lin, D.S., Connor, W.S., 2005. Can prenatal N-3 fatty acid
deciency be completely reversed after birth? Eects on retinal and brain bio-
chemistry and visual function in rhesus monkeys. Pediatr. Res. 58, 865872.
Ariel, A., Li, P.L., Wang, W., Tang, W.X., Fredman, G., Hong, S., et al., 2005. The doc-
osatriene protectin D1 is produced by T H 2 skewing promotes human T cell via lipid
raft clustering. J. Biol. Chem. 280, 4307943086.
Ariel, A., Serhan, C.N., 2012. New lives given by cell death: macrophage dierentiation
following their encounter with apoptotic leukocytes during the resolution of in-
ammation. Front. Immunol. 4.
Authority, E.F.S., 2011. Scientic Opinion on the substantiation of health claims related
to docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA). EFSA J. 8, 10.
Balas, L., Durand, T., 2016. Dihydroxylated E,E,Z-docosatrienes. An overview of their
synthesis and biological signicance. Prog. Lipid Res. 61, 118.
Basak, S., Das, M.K., Duttaroy, A.K., 2013. Fatty acid-induced angiogenesis in rst tri-
mester placental trophoblast cells: possible roles of cellular fatty acid-binding pro-
teins. Life Sci. 93, 755762.
Bauer, I., Hughes, M., Rowsell, R., Cockerell, R., Pipingas, A., Crewther, S., et al., 2014.
Omega-3 supplementation improves cognition and modies brain activation in young
adults. Hum. Psychopharmacol. 29, 133144.
Bazan, N.G., 2005. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects
brain and retina against cell injury-induced oxidative stress. Brain Pathol. (Zurich,
Switzerland) 15, 1526715278.
Bazan, N.G., 2006. Cell survival matters: docosahexaenoic acid signaling, neuroprotection
and photoreceptors. Trends Neurosci. 263271.
Bazan, N.G., Molina, M.F., Gordon, W.C., 2011. Docosahexaenoic acid signalolipidomics
in nutrition: signicance in aging, neuroinammation, macular degeneration,
Alzheimers, and other neurodegenerative diseases. Annu. Rev. Nutr. 31, 321351.
Bazinet, R.P., Layé, S., 2014. Polyunsaturated fatty acids and their metabolites in brain
function and disease. Nat. Rev. Neurosci. 771785.
Bisicchia, E., Sasso, V., Catanzaro, G., Leuti, A., Besharat, Z.M., Chiacchiarini, M., et al.,
2018. Resolvin D1 halts remote neuroinammation and improves functional recovery
after focal brain damage via ALX/FPR2 receptor-regulated MicroRNAs. Mol.
Table 4
Various clinical studies of DHA supplementation in relation with brain function.
Study Experimental setting Observed outcome
The Kansas University DHA outcome study (KUDOS) Cognitive and behavioral development Improvement of visual attention among infants has been observed
with the reduction of preterm birth risk (Colombo et al., 2019).
DHA supplementation on developmental outcomes of
toddlers born preterm
Developmental outcomes of toddlers Daily supplementation of DHA didnt improve cognitive function and
negative eects on language development in certain subgroups of
children (Keim et al., 2018).
Eect of DHA supplementation during pregnancy on
maternal depression and neurodevelopment of young
Neurodevelopmental outcome of children No reduction in postpartum depression in mothers nor improved
cognitive and language development in their ospring during early
childhood (Makrides et al., 2009).
Neurodevelopmental outcomes of preterm infants fed high-
dose docosahexaenoic acid
Neurodevelopment at 18 months age. Did not increase Bayley mental development index scores of preterm
infants overall born earlier than 33 weeks, but improved the Bayley
mental development index scores of girls (Makrides et al., 2009)
Neurodevelopmental outcomes at 7 years' corrected age in
preterm infants who were fed high-dose DHA to term
Cognitive outcome detected at 18 months
Did not show any evidence of benet (Collins et al., 2015).
Feeding preterm infants milk with a higher dose of DHA
than that used in current practice
Language or behavior in early childhood. Did not result in any clinically meaningful change to language
development or behavior when assessed in early childhood (Smithers
et al., 2008).
DHA supplementation in children with ADHD DHA supplementation for 4 months
decreases the symptoms or not
No statistically signicant improvement of ADHD symptoms(Voigt
et al., 2001)
Maternal consumption of a DHA-containing functional food
during pregnancy: memory tasks at age 9 months
Problem-solving abilities and recognition
Enhancement of problem-solving
skills but not recognition skills
at 9 months of age of infants(Judge et al., 2007)
DHA supplementation slows cognitive decline in Alzheimer
disease or not
DHA supplementation in individuals with
mild to moderate Alzheimer disease
DHA supplementation led to no benecial
eect on rate of cognitive and functional
decline (Quinn et al., 2010a).
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
Neurobiol. 55, 68946905.
Bos, D.J., Oranje, B., Veerhoek, E.S., Van Diepen, R.M., Weusten, J.M.H., Demmelmair,
H., et al., 2015. Reduced symptoms of inattention after dietary omega-3 fatty acid
supplementation in boys with and without attention decit/hyperactivity disorder.
Neuropsychopharmacology 40, 22982306.
Boudrault, C., Bazinet, R.P., Ma, D.W.L., 2009. Experimental models and mechanisms
underlying the protective eects of n-3 polyunsaturated fatty acids in Alzheimers
disease. J. Nutr. Biochem. 110.
Bourre, J.M., 2005. Dietary omega-3 Fatty acids and psychiatry: mood, behaviour, stress,
depression, dementia and aging. J. Nutr. Health Aging 9.
Bozzatello, P., Brignolo, E., De Grandi, E., Bellino, S., 2016. Supplementation with omega-
3 fatty acids in psychiatric disorders: a review of literature data. J. Clin. Med. 5, 8.
Bradbury, J., 2011. Docosahexaenoic acid (DHA): an ancient nutrient for the modern
human brain. Nutrients 3, 529554.
Brenna, J.T., Carlson, S.E., 2014. Docosahexaenoic acid and human brain development:
evidence that adietary supply is needed for optimal development. J. Hum. Evol. 77,
Burdge, G.C., Jones, A.E., Wootton, S.A., 2002. Eicosapentaenoic and docosapentaenoic
acids are the principal products of α-linolenic acid metabolism in young men. Br. J.
Nutr. 88, 355363.
Burdge, G.C., Wootton, S.A., 2002. Conversion of α-linolenic acid to eicosapentaenoic,
docosapentaenoic and docosahexaenoic acids in young women. Br. J. Nutr. 88,
Calandria, J.M., Marcheselli, V.L., Mukherjee, P.K., Uddin, J., Winkler, J.W., Petasis,
N.A., et al., 2009. Selective survival rescue in 15-lipoxygenase-1-decient retinal
pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neu-
roprotectin D1. J. Biol. Chem. 284, 1787717882.
Calder, P.C., 2013. Omega-3 polyunsaturated fatty acids and inammatory processes:
nutrition or pharmacology? Br. J. Clin. Pharmacol. 75, 645662.
Calder, P.C., 2016. The DHA content of a cell membrane can have a signicant inuence
on cellular behaviour and responsiveness to signals. Ann. Nutr. Metab. 69, 821.
Calderon, F., Kim, H.Y., 2004. Docosahexaenoic acid promotes neurite growth in hip-
pocampal neurons. J. Neurochem. 90, 979988.
Cao, D., Xue, R., Xu, J., Liu, Z., 2005. Eects of docosahexaenoic acid on the survival and
neurite outgrowth of rat cortical neurons in primary cultures. J. Nutr. Biochem. 16,
Cao, D.H., Xu, J.F., Xue, R.H., Zheng, W.F., Liu, Z.L., 2004. Protective eect of chronic
ethyl docosahexaenoate administration on brain injury in ischemic gerbils.
Pharmacol. Biochem. Behav. 79, 651659.
Carlson, S.E., Colombo, J., Gajewski, B.J., Gustafson, K.M., Mundy, D., Yeast, J., et al.,
2013. DHA supplementation and pregnancy outcomes. Am. J. Clin. Nutr. 97,
Carver, J.D., Benford, V.J., Han, B., Cantor, A.B., 2001. The relationship between age and
the fatty acid composition of cerebral cortex and erythrocytes in human subjects.
Brain Res. Bull. 56, 7985.
Chalon, S., 2006. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins
Leukot. Essent. Fatty Acids 75, 259269.
Chan, J.P., Wong, B.H., Chin, C.F., Galam, D.L.A., Foo, J.C., Wong, L.C., et al., 2018. The
lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain. PLoS Biol.
16, e2006443.
Chapkin, R.S., Mcmurray, D.N., Davidson, L.A., Patil, B.S., Fan, Y.Y., Lupton, J.R., 2008.
Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br. J. Nutr.
Chen, C.T., Liu, Z., Ouellet, M., Calon, F., Bazinet, R.P., 2009. Rapid β-oxidation of ei-
cosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot. Essent.
Fatty Acids 80, 157163.
Chen, H.F., Su, H.M., 2013. Exposure to a maternal n-3 fatty acid-decient diet during
brain development provokes excessive hypothalamic-pituitary-adrenal axis responses
to stress and behavioral indices of depression and anxiety in male rat ospring later
in life. J. Nutr. Biochem. 24, 7080.
Chilton, F.H., Murphy, R.C., Wilson, B.A., Sergeant, S., Ainsworth, H., Seeds, M.C., et al.,
2014. Diet-gene interactions and PUFA metabolism: a potential contributor to health
disparities and human diseases. Nutrients 19932022.
Coti Bertrand, P., OKusky, J.R., Innis, S.M., 2006. Maternal dietary (n-3) fatty acid de-
ciency alters neurogenesis in the embryonic rat brain. J. Nutr. 136, 15701575.
Crane, D.I., 2014. Revisiting the neuropathogenesis of Zellweger syndrome. Neurochem.
Int. 69, 18.
Cunnane, S.C., Chouinard-Watkins, R., Castellano, C.A., Barberger-Gateau, P., 2013.
Docosahexaenoic acid homeostasis, brain aging and Alzheimers disease: Can we
reconcile the evidence? Prostaglandins Leukot. Essent. Fatty Acids 88, 6170.
DAddario, C., Micioni Di Bonaventura, M.V., Pucci, M., Romano, A., Gaetani, S.,
Ciccocioppo, R., et al., 2014. Endocannabinoid signaling and food addiction.
Neurosci. Biobehav. Rev. 203224.
Dalli, J., Winkler, J.W., Colas, R.A., Arnardottir, H., Cheng, C.Y.C., Chiang, N., et al.,
2013. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents.
Chem. Biol. 20, 188201.
Davis, B.C., Kris-Etherton, P.M., 2003. Achieving optimal essential fatty acid status in
vegetarians: current knowledge and practical implications. Am. J. Clin. Nutr. 78 (3
Suppl), 640S646S.
De Petrocellis, L., Melck, D., Bisogno, T., Milone, A., Di Marzo, V., 1999. Finding of the
endocannabinoid signalling system in Hydra, a very primitive organism: possible role
in the feeding response. Neuroscience 92, 377387.
Diep, Q.N., Touyz, R.M., Schirin, E.L., 2000. Docosahexaenoic acid, a peroxisome pro-
liferator-activated receptor-αligand, induces apoptosis in vascular smooth muscle
cells by stimulation of p38: mitogen-activated protein kinase. Hypertension 36,
Duttaroy, A.K., 2000. Transport mechanisms for long-chain polyunsaturated fatty acids in
the human placenta. Am. J. Clin. Nutr. 71 (1 Suppl) 315S-22S.
Duttaroy, A.K., 2009. Transport of fatty acids across the human placenta: a review. Prog.
Lipid Res. 48, 5261.
Duttaroy, A.K., 2016. Docosahexaenoic acid supports feto-placental growth andprotects
cardiovascular and cognitive function: a mini review. Eur. J. Lipid Sci. Technol. 118,
Duvall, M.G., Levy, B.D., 2016. DHA- and EPA-derived resolvins, protectins, and maresins
in airway inammation. Eur. J. Pharmacol. 785, 144155.
Dyall, S.C., 2015. Long-chain omega-3 fatty acids and the brain: a review of the in-
dependent and shared eects of EPA, DPA and DHA. Front. Aging Neurosci. 52.
EFSAReport, 2019. EFSA Panel on Dietetic Products NaA. Scientic opinion on the tol-
erable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid
(DHA) and docosapentaenoic acid (DPA). EFSA J. 10, 2815.
Farooqui, A., 2012. N-3 fatty acid-derived lipid mediators in the brain: new weapons
against oxidative stress and inammation. Curr. Med. Chem. 19, 532543.
Forsyth, S., Gautier, S., Salem, N., 2016. Global estimates of dietary intake of doc-
osahexaenoic acid and arachidonic acid in developing and developed countries. Ann.
Nutr. Metab. 68, 258267.
Francos-Quijorna, I., Santos-Nogueira, E., Gronert, K., Sullivan, A.B., Kopp, M.A.,
Brommer, B., et al., 2017. Maresin 1 promotes inammatory resolution, neuropro-
tection, and functional neurological recovery after spinal cord injury. J. Neurosci. 37,
García-Sastre, A., 2013. XLessons from lipids in the ght against inuenza. Cell 2223.
Gladine, C., Laurie, J.-C., Giulia, C., Dominique, B., Corinne, C., Nathalie, H., et al., 2014.
Neuroprostanes, produced by free-radical mediated peroxidation of DHA, inhibit the
inammatory response of human macrophages. Free Radic. Biol. Med. 75, S15S25.
Goustard-Langelier, B., Guesnet, P., Durand, G., Antoine, J.M., Alessandri, J.M., 1999. n-3
and n-6 Fatty acid enrichment by dietary sh oil and phospholipid sources in brain
cortical areas and nonneural tissues of formula-fed piglets. Lipids 34, 516.
Green, P., Glozman, S., Weiner, L., Yavin, E., 2001. Enhanced free radical scavenging and
decreased lipid peroxidation in the rat fetal brain after treatment with ethyl doc-
osahexaenoate. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1532, 203212.
Groeger, A.L., Cipollina, C., Cole, M.P., Woodcock, S.R., Bonacci, G., Rudolph, T.K., et al.,
2010. Cyclooxygenase-2 generates anti-inammatory mediators from omega-3 fatty
acids. Nat. Chem. Biol. 6, 433441.
Grosseld, A., Feller, S.E., Pitman, M.C., 2006. A role for direct interactions in the
modulation of rhodopsin by -3 polyunsaturated lipids. Proc. Natl. Acad. Sci. U. S. A.
103, 48884893.
Hashimoto, M., Hossain, S., Agdul, H., Shido, O., 2005. Docosahexaenoic acid-induced
amelioration on impairment of memory learning in amyloid β-infused rats relates to
the decreases of amyloid βand cholesterol levels in detergent-insoluble membrane
fractions. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1738, 9198.
Hennebelle, M., Balasse, L., Latour, A., Champeil-Potokar, G., Denis, S., Lavialle, M.,
et al., 2012. Inuence of omega-3 fatty acid status on the way rats adapt to chronic
restraint stress. PLoS One 7, e42142.
Hibbeln, J.R., 1998. Fish consumption and major depression [9]. Lancet 1213.
Homan, D.R., Hughbanks-Wheaton, D.K., Pearson, N.S., Fish, G.E., Spencer, R., Takacs,
A., et al., 2014. Four-year placebo-controlled trial of docosahexaenoic acid in X-
linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA
Ophthalmol. 132, 866873.
Homan, D.R., Hughbanks-Wheaton, D.K., Spencer, R., Fish, G.E., Pearson, N.S., Wang,
Y.Z., et al., 2015. Docosahexaenoic acid slows visual eld progression in X-linked
retinitis pigmentosa: ancillary outcomes of the DHAX trial. Invest. Ophthalmol. Vis.
Sci. 56, 66466653.
Hong, S., Tjonahen, E., Morgan, E.L., Lu, Y., Serhan, C.N., Rowley, A.F., 2005. Rainbow
trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-
derived resolvins and protectins - mediator lipidomic analysis. Prostaglandins Other
Lipid Mediat. 78, 107116.
Huang, L.H., Chung, H.Y., Su, H.M., 2017. Docosahexaenoic acid reduces sterol reg-
ulatory element binding protein-1 and fatty acid synthase expression and inhibits cell
proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
BMC Cancer 17, 890.
Innis, S.M., 1991. Essential fatty acids in growth and development. Prog. Lipid Res.
Innis, S.M., 2008. Dietary omega 3 fatty acids and the developing brain. Brain Res. 3543.
Innis, S.M., 2018. Dietary (n-3) fatty acids and brain development. J. Nutr. 137, 855859.
Insua, M.F., Garelli, A., Rotstein, N.P., German, O.L., Arias, A., Politi, L.E., 2003. Cell
cycle regulation in retinal progenitors by glia-derived neurotrophic factor and doc-
osahexaenoic acid. Invest. Ophthalmol. Vis. Sci. 44, 22352244.
Jaremka, L.M., Derry, H.M., Bornstein, R., Prakash, R.S., Peng, J., Belury, M.A., et al.,
2014. Omega-3 supplementation and loneliness-related memory problems: secondary
analyses of a randomized controlled trial. Psychosom. Med. 76, 650658.
Johnsen, G.M., Basak, S., Weedon-Fekjaer, M.S., Sta, A.C., Duttaroy, A.K., 2011.
Docosahexaenoic acid stimulates tube formation in rst trimester trophoblast cells,
HTR8/SVneo. Placenta 32, 626632.
Judge, M.P., Harel, O., Lammi-Keefe, C.J., 2007. Maternal consumption of a doc-
osahexaenoic acid-containing functional food during pregnancy: benet for infant
performance on problem-solving but not on recognition memory tasks at age 9 mo.
Am. J. Clin. Nutr. 85, 15721577.
Julvez, J., Mendez, M., Fernandez-Barres, S., Romaguera, D., Vioque, J., Llop, S., et al.,
2016. Maternal consumption of seafood in pregnancy and child neuropsychological
development: a longitudinal study based on a population with high consumption
levels. Am. J. Epidemiol. 183, 169182.
Kawakita, E., Hashimoto, M., Shido, O., 2006. Docosahexaenoic acid promotes neuro-
genesis in vitro and in vivo. Neuroscience 139, 991997.
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
Kiecolt-Glaser, J.K., Belury, M.A., Andridge, R., Malarkey, W.B., Glaser, R., 2011. Omega-
3 supplementation lowers inammation and anxiety in medical students: a rando-
mized controlled trial. Brain Behav. Immun. 25, 17251734.
Kiliaan, A., Königs, A., 2016. Critical appraisal of omega-3 fatty acids in attention-decit/
hyperactivity disorder treatment. Neuropsychiatr. Dis. Treat. 12, 18691882.
Kim, J., Carlson, M.E., Watkins, B.A., 2014. Docosahexaenoyl ethanolamide improves
glucose uptake and alters endocannabinoid system gene expression in proliferating
and dierentiating C2C12 myoblasts. Front. Physiol. 5.
Kinney, J.W., Bemiller, S.M., Murtishaw, A.S., Leisgang, A.M., Salazar, A.M., Lamb, B.T.,
2018. Inammation as a central mechanism in Alzheimers disease. Alzheimers
Dement. (N. Y.) 4, 575590.
Kitajka, K., Puskas, L.G., Zvara, A., Hackler, L., Barcelo-Coblijn, G., Yeo, Y.K., et al., 2002.
The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene
expression by dietary n-3 fatty acids. Proc. Natl. Acad. Sci. U. S. A. 99, 26192624.
Klein, C.P., Sperotto, N.D.M., Maciel, I.S., Leite, C.E., Souza, A.H., Campos, M.M., 2014.
Eects of D-series resolvins on behavioral and neurochemical changes in a -
bromyalgia-like model in mice. Neuropharmacology 86, 5766.
Koletzko, B., Cetin, I., Brenna, J.T., 2007. Perinatal Lipid Intake Working G, Child Health
F, Diabetic Pregnancy Study G, et al. Dietary fat intakes for pregnant and lactating
women. Br. J. Nutr. 98, 873877.
Kuda, O., 2017. Bioactive metabolites of docosahexaenoic acid. Biochimie 1220.
Laugero, K.D., Smilowitz, J.T., German, J.B., Jarcho, M.R., Mendoza, S.P., Bales, K.L.,
2011. Plasma omega 3 polyunsaturated fatty acid status and monounsaturated fatty
acids are altered by chronic social stress and predict endocrine responses to acute
stress in titi monkeys. Prostaglandins Leukot. Essent. Fatty Acids 84, 7178.
Lauritzen, L., Brambilla, P., Mazzocchi, A., Harsløf, L.B.S., Ciappolino, V., Agostoni, C.,
2016. DHA eects in brain development and function. Nutrients 6.
Lengqvist, J., Mata de Urquiza, A., Bergman, A.-C., Willson, T.M., Sjövall, J., Perlmann,
T., et al., 2004. Polyunsaturated fatty acids including docosahexaenoic and arachi-
donic acid bind to the retinoid X receptor αligand-binding domain. Mol. Cell.
Proteom. 3, 692703.
Li, Q., Wang, M., Tan, L., Wang, C., Ma, J., Li, N., et al., 2005. Docosahexaenoic acid
changes lipid composition and interleukin-2 receptor signaling in membrane rafts. J.
Lipid Res. 46, 19041913.
Lim, J.Y., Park, C.-K., Hwang, S.W., 2015. Biological roles of resolvins and related sub-
stances in the resolution of pain. Biomed Res. Int. 2015.
Lima-Garcia, J.F., Dutra, R.C., Da Silva, K.A.B.S., Motta, E.M., Campos, M.M., Calixto,
J.B., 2011. The precursor of resolvin D series and aspirin-triggered resolvin D1 dis-
play anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J.
Pharmacol. 164, 278293.
Lin, P.Y., Su, K.P., 2007. A meta-analytic review of double-blind, placebo-controlled trials
of antidepressant ecacy of omega-3 fatty acids. J. Clin. Psychiatry 68, 10561061.
Liu, A., Lin, Y., Terry, R., Nelson, K., Bernstein, P.S., 2011. Role of long-chain and very-
long-chain polyunsaturated fatty acids in macular degenerations and dystrophies.
Clin. Lipidol. 6, 593613.
Lu, H.C., MacKie, K., 2016. An introduction to the endogenous cannabinoid system. Biol.
Psychiatry 516525.
Lucas, M., Dewailly, É., Blanchet, C., Gingras, S., Holub, B.J., 2009. Plasma omega-3 and
psychological distress among Nunavik Inuit (Canada). Psychiatry Res. 167, 266278.
Lukiw, W.J., Cui, J.G., Marcheselli, V.L., Bodker, M., Botkjaer, A., Gotlinger, K., et al.,
2005. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell
survival and Alzheimer disease. J. Clin. Invest. 115, 27742783.
Lupien, S.J., McEwen, B.S., Gunnar, M.R., Heim, C., 2009. Eects of stress throughout the
lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 434445.
Maes, M., Christophe, A., Bosmans, E., Lin, A., Neels, H., 2000. In humans, serum poly-
unsaturated fatty acid levels predict the response of proinammatory cytokines to
psychologic stress. Biol. Psychiatry 47, 910920.
Makrides, M., Gibson, R.A., McPhee, A.J., Collins, C.T., Davis, P.G., Doyle, L.W., et al.,
2009. Neurodevelopmental outcomes of preterm infants fed high-dose docosahex-
aenoic acid: a randomized controlled trial. JAMA 301, 175182.
Marangell, L.B., Martinez, J.M., Zboyan, H.A., Kertz, B., Kim, H.F.S., Puryear, L.J., 2003.
A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic
acid in the treatment of major depression. Am. J. Psychiatry 160, 996998.
Masoodi, M., Kuda, O., Rossmeisl, M., Flachs, P., Kopecky, J., 2015. Lipid signaling in
adipose tissue: connecting inammation & metabolism. Biochim. Biophys. Acta
Mol. Cell Biol. Lipids 503518.
McEwen, B.S., 2010. Stress, sex, and neural adaptation to a changing environment: me-
chanisms of neuronal remodeling. Ann. N. Y. Acad. Sci. 1204, E38E59.
McNamara, R.K., 2010. DHA deciency and prefrontal cortex neuropathology in re-
current aective disorders. J. Nutr. 140, 864868.
McNamara, R.K., Hahn, C.G., Jandacek, R., Rider, T., Tso, P., Stanford, K.E., et al., 2007.
Selective decits in the omega-3 fatty acid docosahexaenoic acid in the postmortem
orbitofrontal cortex of patients with major depressive disorder. Biol. Psychiatry 62,
Metherel, A.H., Irfan, M., Klingel, S.L., Mutch, D.M., Bazinet, R.P., 2019. Compound-
specic isotope analysis reveals no retroconversion of DHA to EPA but substantial
conversion of EPA to DHA following supplementation: a randomized control trial.
Am. J. Clin. Nutr. 19.
Mita, R., Beaulieu, M.J., Field, C., Godbout, R., 2010. Brain fatty acid-binding protein and
ω-3/ω-6 fatty acids. J. Biol. Chem. 285, 3700537015.
Mori, T.A., Burke, V., Puddey, I.B., Watts, G.F., ONeal, D.N., Best, J.D., et al., 2000a.
Puried eicosapentaenoic and docosahexaenoic acids have dierential eects on
serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hy-
pedipidemic men. Am. J. Clin. Nutr. 71, 10851094.
Mori, T.A., Watts, G.F., Burke, V., Hilme, E., Puddey, I.B., Beilin, L.J., 2000b. Dierential
eects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of
the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102,
Morita, M., Kuba, K., Ichikawa, A., Nakayama, M., Katahira, J., Iwamoto, R., et al., 2013.
The lipid mediator protectin D1 inhibits inuenza virus replication and improves
severe inuenza. Cell 153, 112125.
Mulder, K.A., King, D.J., Innis, S.M., 2014. Omega-3 fatty acid deciency in infants before
birth identied using a randomized trial of maternal DHA supplementation in
pregnancy. PLoS One 9, e83764.
Murray, Christopher J.L., Lopez, Alan D., World Health Organization, World Bank &
Harvard School of Public Health, 1996. The Global Burden of Disease: A
Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and
Risk Factors in 1990 and Projected to 2020 : Summary / edited by Christopher J. L.
Murray, Alan D. Lopez. World Health Organization.
Myhrstad, M.C., Ottestad, I., Gunther, C.C., Ryeng, E., Holden, M., Nilsson, A., et al.,
2016. The PBMC transcriptome prole after intake of oxidized versus high-quality
sh oil: an explorative study in healthy subjects. Genes Nutr. 11, 16.
Ne, L.M., Culiner, J., CunninghamRundles, S., Seidman, C., Meehan, D., Maturi, J.,
et al., 2010. Algal docosahexaenoic acid aects plasma lipoprotein particle size dis-
tribution in overweight and obese adults. J. Nutr. 141, 207213.
Nguyen, L.N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., et al., 2014.
Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid.
Nature 509, 503506.
OBrien, J.S., Sampson, E.L., 1965. Lipid composition of the normal human brain: gray
matter, white matter, and myelin. J. Lipid Res. 6, 545551.
Oh, D.Y., Walenta, E., Akiyama, T.E., Lagakos, W.S., Lackey, D., Pessentheiner, A.R.,
et al., 2014. A Gpr120-selective agonist improves insulin resistance and chronic in-
ammation in obese mice. Nat. Med. 20, 942947.
Okada, M., Amamoto, T., Tomonaga, M., Kawachi, A., Yazawa, K., Mine, K., et al., 1996.
The chronic administration of docosahexaenoic acid reduces the spatial cognitive
decit following transient forebrain ischemia in rats. Neuroscience 71, 1725.
Orlowski, J.P., 1999. Whatever happened to Reyes syndrome? Did it ever really exist?
Crit. Care Med. 27, 15821587.
Owada, Y., Abdelwahab, S.A., Kitanaka, N., Sakagami, H., Takano, H., Sugitani, Y., et al.,
2006. Altered emotional behavioral responses in mice lacking brain-type fatty acid-
binding protein gene. Eur. J. Neurosci. 24, 175187.
Parellada, M., Llorente, C., Calvo, R., Gutierrez, S., Lázaro, L., Graell, M., et al., 2017.
Randomized trial of omega-3 for autism spectrum disorders: eect on cell membrane
composition and behavior. Eur. Neuropsychopharmacol. 27, 13191330.
Park, H.G., Lawrence, P., Engel, M.G., Kothapalli, K., Brenna, J.T., 2016. Metabolic fate of
docosahexaenoic acid (DHA; 22:6n-3) in human cells: direct retroconversion of DHA
to eicosapentaenoic acid (20:5n-3) dominates over elongation to tetracosahexaenoic
acid (24:6n-3). FEBS Lett. 31883194.
Parra-Cabrera, S., Stein, A.D., Wang, M., Martorell, R., Rivera, J., Ramakrishnan, U.,
2011. Dietary intakes of polyunsaturated fatty acids among pregnant Mexican
women. Matern. Child Nutr. 7, 140147.
Peet, M., Horrobin, D.F., 2002. A dose-ranging study of the eects of ethyl-eicosa-
pentaenoate in patients with ongoing depression despite apparently adequate treat-
ment with standard drugs. Arch. Gen. Psychiatry 59, 913919.
Piazza, P.V., Lafontan, M., Girard, J., 2007. Integrated physiology and pathophysiology of
CB1-mediated eects of the endocannabinoid system. Diabetes Metab. 97107.
Plourde, M., Cunnane, S.C., 2008. Erratum: extremely limited synthesis of long-chain
polyunsaturates in adults: implications for their dietary essentiality and use as sup-
plements. Appl. Physiol. Nutr. Metab. 32, 619634.
Pusceddu, M.M., Kelly, P., Stanton, C., Cryan, J.F., Dinan, T.G., 2016. N-3 poly-
unsaturated fatty acids through the lifespan: implication for psychopathology. Int. J.
Neuropsychopharmacol. 19.
Qawasmi, A., Landeros-Weisenberger, A., Leckman, J.F., Bloch, M.H., 2012. Meta-ana-
lysis of long-chain polyunsaturated fatty acid supplementation of formula and infant
cognition. Pediatrics 129, 11411149.
Qu, Q., Xuan, W., Fan, G.H., 2015. Roles of resolvins in the resolution of acute in-
ammation. Cell Biol. Int. 322.
Quinn, J.F., Raman, R., Thomas, R.G., Yurko-Mauro, K., Nelson, E.B., Van Dyck, C., et al.,
2010a. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer
disease: a randomized trial. JAMA 304, 19031911.
Quinn, J.F., Raman, R., Thomas, R.G., Yurko-Mauro, K., Nelson, E.B., Van Dyck, C., et al.,
2010b. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer
disease: a randomized trial. JAMA J. Am. Med. Assoc. 304, 19031911.
Ramalho, R., Pereira, A.C., Vicente, F., Pereira, P., 2018. Docosahexaenoic acid supple-
mentation for children with attention decit hyperactivity disorder: a comprehensive
review of the evidence. Clin. Nutr. ESPEN 25, 17.
Ranabir, S., Reetu, K., 2011. Stress and hormones. Indian J. Endocrinol. Metab. 15,
Recchiuti, A., Krishnamoorthy, S., Fredman, G., Chiang, N., Serhan, C.N., 2010.
MicroRNAs in resolution of acute inammation: identication of novel resolvin D1-
miRNA circuits. FASEB J. 25, 544560.
Rioux, L., Arnold, S.E., 2005. The expression of retinoic acid receptor alpha is increased in
the granule cells of the dentate gyrus in schizophrenia. Psychiatry Res. 133, 1321.
Robertson, R., Guihéneuf, F., Stengel, D.B., Fitzgerald, G., Ross, P., Stanton, C., 2013.
Algae-derived polyunsaturated fatty acids: implications for human health.
Polyunsaturated Fatty Acids Sources, Antioxidant Properties and Health Benets.
Salem, N., Eggersdorfer, M., 2015. Is the world supply of omega-3 fatty acids adequate for
optimal human nutrition? Curr. Opin. Clin. Nutr. Metab. Care 18, 147154.
Salem, N., Litman, B., Kim, H.Y., Gawrisch, K., 2001. Mechanisms of action of doc-
osahexaenoic acid in the nervous system. Lipids 36, 945959.
Sato, M., Adan, Y., Shibata, K., Shoji, Y., Sato, H., Imaizumi, K., 2001. Cloning of rat delta
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
6-desaturase and its regulation by dietary eicosapentaenoic or docosahexaenoic acid.
World Rev. Nutr. Diet. 88, 196199.
Schaefer, E.J., Bongard, V., Beiser, A.S., Lamon-Fava, S., Robins, S.J., Au, R., et al., 2006.
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and
alzheimer disease: The framingham heart study. Arch. Neurol. 63, 15451550.
Seidl, S.E., Santiago, J.A., Bilyk, H., Potashkin, J.A., 2014. The emerging role of nutrition
in Parkinsons disease. Front. Aging Neurosci. 6, 36.
Serhan, C.N., 2014. Pro-resolving lipid mediators are leads for resolution physiology.
Nature 92101.
Serhan, C.N., Chiang, N., Dalli, J., Levy, B.D., 2015a. Lipid mediators in the resolution of
inammation. Cold Spring Harb. Perspect. Biol. 7, a016311.
Serhan, C.N., Dalli, J., Colas, R.A., Winkler, J.W., Chiang, N., 2015b. Protectins and
maresins: New pro-resolving families of mediators in acute inammation and re-
solution bioactive metabolome. Biochim. Biophys. Acta Mol. Cell Biol. Lipids
Serhan, C.N., Dalli, J., Karamnov, S., Choi, A., Park, C.-K., Xu, Z.-Z., et al., 2012.
Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and
controls pain. FASEB J. 26, 17551765.
Serhan, C.N., Yang, R., Martinod, K., Kasuga, K., Pillai, P.S., Porter, T.F., et al., 2008.
Maresins: novel macrophage mediators with potent antiinammatory and proresol-
ving actions. J. Exp. Med. 206, 1523.
Shamim, A., Mahmood, T., Ahsan, F., Kumar, A., Bagga, P., 2018. Lipids: An insight into
the neurodegenerative disorders. Clin. Nutr. Exp. 119.
Sherratt, S.C.R., Mason, R.P., 2018. Eicosapentaenoic acid and docosahexaenoic acid
have distinct membrane locations and lipid interactions as determined by X-ray
diraction. Chem. Phys. Lipids 212, 7379.
Shinohara, M., Serhan, C.N., 2016. Novel endogenous proresolving molecules:essential
fatty acid-derived and gaseous mediators in the resolution of inammation. J.
Atheroscler. Thromb. 23, 655664.
Shulkin, M., Pimpin, L., Bellinger, D., Kranz, S., Fawzi, W., Duggan, C., et al., 2018. N-3
fatty acid supplementation in mothers, preterm infants, and term infants and child-
hood psychomotor and visual development: a systematic review and meta-analysis. J.
Nutr. 149, 409418.
Simmer, K., Patole, S.K., Rao, S.C., 2011. Long-chain polyunsaturated fatty acid supple-
mentation in infants born at term. Cochrane Database Syst. Rev. 4, CD000376.
Simopoulos, A.P., 2016. An increase in the Omega-6/Omega-3 fatty acid ratio increases
the risk for obesity. Nutrients 8, 117.
Singh, M., 2005. Essential fatty acids, DHA and human brain. Indian J. Pediatr. 72,
Smith, S.L., Rouse, C.A., 2017. Docosahexaenoic acid and the preterm infant. Matern.
Health Neonatol. Perinatol. 3, 22.
Smithers, L.G., Gibson, R.A., McPhee, A., Makrides, M., 2008. Eect of long-chain poly-
unsaturated fatty acid supplementation of preterm infants on disease risk and neu-
rodevelopment: a systematic review of randomized controlled trials. Am. J. Clin.
Nutr. 87, 912920.
Soderstrom, K., 2004. Endocannabinoids link feeding state and auditory perception-re-
lated gene expression. J. Neurosci. 24, 1001310024.
Song, C., Manku, M.S., Horrobin, D.F., 2008. Long-chain polyunsaturated fatty acids
modulate interleukin-1βinduced changes in behavior, monoaminergic neuro-
transmitters, and brain inammation in rats. J. Nutr. 138, 954963.
Souied, E.H., Aslam, T., Garcia-Layana, A., Holz, F.G., Leys, A., Silva, R., et al., 2015.
Omega-3 fatty acids and age-related macular degeneration. Ophthalmic Res. 55,
Spite, M., Clària, J., Serhan, C.N., 2014. Resolvins, specialized proresolving lipid med-
iators, and their potential roles in metabolic diseases. Cell Metab. 2136.
Stables, M.J., Shah, S., Camon, E.B., Lovering, R.C., Newson, J., Bystrom, J., et al., 2011.
Transcriptomic analyses of murine resolution-phase macrophages. Blood 118,
Stillwell, W., Shaikh, S.R., Zerouga, M., Siddiqui, R., Wassall, S.R., 2005.
Docosahexaenoic acid aects cell signaling by altering lipid rafts. Reprod. Nutr. Dev.
45, 559579.
Sun, G.Y., Li, R., Yang, B., Fritsche, K.L., Beversdorf, D.Q., Lubahn, D.B., et al., 2019.
Quercetin potentiates docosahexaenoic acid to suppress lipopolysaccharide-induced
oxidative/inammatory responses, alter lipid peroxidation products, and enhance the
adaptive stress pathways in BV-2 microglial cells. Int. J. Mol. Sci. 20.
Sun, G.Y., Simonyi, A., Fritsche, K.L., Chuang, D.Y., Hannink, M., Gu, Z., et al., 2018.
Docosahexaenoic acid (DHA): an essential nutrient and a nutraceutical for brain
health and diseases. Prostaglandins Leukot. Essent. Fatty Acids 136, 313.
Suzuki, H., Manabe, S., Wada, O., Crawford, M.A., 1997. Rapid incorporation of
docosahexaenoic acid from dietary sources into brain microsomal, synaptosomal and
mitochondrial membranes in adult mice. Int. J. Vitam. Nutr. Res. 67, 272278.
Tracey, T.J., Steyn, F.J., Wolvetang, E.J., Ngo, S.T., 2018. Neuronal lipid metabolism:
multiple pathways driving functional outcomes in health and disease. Front. Mol.
Neurosci. 11, 10.
Trépanier, M.O., Hopperton, K.E., Orr, S.K., Bazinet, R.P., 2016. N-3 polyunsaturated
fatty acids in animal models with neuroinammation: an update. Eur. J. Pharmacol.
785, 187206.
Ulven, S.M., Holven, K.B., 2015. Comparison of bioavailability of krill oil versus sh oil
and health eect. Vascular Health and Risk Management.
Valenti, M., Cottone, E., Martinez, R., De Pedro, N., Rubio, M., Viveros, M.P., et al., 2005.
The endocannabinoid system in the brain of Carassius auratus and its possible role in
the control of food intake. J. Neurochem. 95, 662672.
Van Gelder, B.M., Tijhuis, M., Kalmijn, S., Kromhout, D., 2007. Fish consumption, n-3
fatty acids, and subsequent 5-y cognitive decline in elderly men: The Zutphen Elderly
Study. Am. J. Clin. Nutr. 85, 11421147.
Veerkamp, J.H., Zimmerman, A.W., 2001. Fatty acid-binding proteins of nervous tissue. J.
Mol. Neurosci. 16, 133142.
Voigt, R.G., Llorente, A.M., Jensen, C.L., Fraley, J.K., Berretta, M.C., Heird, W.C., 2001. A
randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supple-
mentation in children with attention-decit/hyperactivity disorder. J. Pediatr. 139,
Vreugdenhil, M., Bruehl, C., Voskuyl, R.A., Kang, J.X., Leaf, A., Wadman, W.J., 2002.
Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons.
Proc. Natl. Acad. Sci. U. S. A. 93, 1255912663.
Wada, K., Nakajima, A., Katayama, K., Kudo, C., Shibuya, A., Kubota, N., et al., 2006.
Peroxisome proliferator-activated receptor γ-mediated regulation of neural stem cell
proliferation and dierentiation. J. Biol. Chem. 281, 1267312681.
Wagner, J.J., Alger, B.E., 1996. Increased neuronal excitability during depolarization-
induced suppression of inhibition in rat hippocampus. J. Physiol. 495, 107112.
Watanabe, S., Doshi, M., Hamazaki, T., 2003. n-3 Polyunsaturated fatty acid (PUFA)
deciency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol
level in mice. Prostaglandins Leukot. Essent. Fatty Acids 69, 5159.
Weiser, M.J., Butt, C.M., Mohajeri, M.H., 2016. Docosahexaenoic acid and cognition
throughout the lifespan. Nutrients 99.
Westphal, C., Konkel, A., Schunck, W.H., 2011. CYP-eicosanoids - A new link between
omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 99108.
WHO, FAO, 2008. Expert Consultation on Fats and Fatty Acids in Human Nutrition.
Interim Summary of Conclusions and Dietary Recommendations on Total Fat & Fatty
Acids. World Health Organization Technical Report Series, pp. 89.
Wilson, R.I., Nicoll, R.A., 2002. Neuroscience: endocannabinoid signaling in the brain.
Science 678682.
Wu, A., Noble, E.E., Tyagi, E., Ying, Z., Zhuang, Y., Gomez-Pinilla, F., 2015. Curcumin
boosts DHA in the brain: implications for the prevention of anxiety disorders.
Biochim. Biophys. Acta Mol. Basis Dis. 1852, 951961.
Wu, J., Cho, E., Giovannucci, E.L., Rosner, B.A., Sastry, S.M., Willett, W.C., et al., 2017.
Dietary intakes of eicosapentaenoic acid and docosahexaenoic acid and risk of age-
related macular degeneration. Ophthalmology 124, 634643.
Yanes, O., Clark, J., Wong, D.M., Patti, G.J., Sánchez-Ruiz, A., Benton, H.P., et al., 2010.
Metabolic oxidation regulates embryonic stem cell dierentiation. Nat. Chem. Biol. 6,
Yang, T., Xu, G., Newton, P.T., Chagin, A.S., Mkrtchian, S., Carlström, M., et al., 2019.
Maresin 1 attenuates neuroinammation in a mouse model of perioperative neuro-
cognitive disorders. Br. J. Anaesth. 122, 350360.
Yurko-Mauro, K., McCarthy, D., Rom, D., Nelson, E.B., Ryan, A.S., Blackwell, A., et al.,
2010. Benecial eects of docosahexaenoic acid on cognition in age-related cognitive
decline. Alzheimers Dement. 6, 456464.
Zhang, M.J., Spite, M., 2012. Resolvins: anti-inammatory and proresolving mediators
derived from omega-3 polyunsaturated fatty acids. Annu. Rev. Nutr. 32, 203207.
Zhao, Y., Calon, F., Julien, C., Winkler, J.W., Petasis, N.A., Lukiw, W.J., et al., 2011.
Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via se-
cretase- and PPARγ-mediated mechanisms in Alzheimers disease models. PLoS One
6, e15816.
Zúñiga, J., Cancino, M., Medina, F., Varela, P., Vargas, R., Tapia, G., et al., 2011. N-3
PUFA supplementation triggers PPAR-αactivation and PPAR-α/NF-κB interaction:
anti-inammatory implications in liver ischemia-reperfusion injury. PLoS One 6 (12),
Zuo, G., Zhang, D., Mu, R., Shen, H., Li, X., Wang, Z., et al., 2018. Resolvin D2 protects
against cerebral ischemia/reperfusion injury in rats. Mol. Brain 11, 113.
R. Mallick, et al. International Journal of Developmental Neuroscience 79 (2019) 21–31
... In addition, 9-HODE is reported as a ligand of GPR132 28 . Docosahexaenoic acid (DHA), essential for eicosanoid production and bioactive in itself, is involved in 4-HDoHE production 29 . Information regarding the effect of PEA, 9-HODE, and 4-HDoHE on the urinary tract is limited. ...
Full-text available
Dysregulation of circadian rhythm can cause nocturia. Levels of fatty acid metabolites, such as palmitoylethanolamide (PEA), 9-hydroxy-10E,12Z-octadecadienoic acid (9-HODE), and 4-hydroxy-5E,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (4-HDoHE), are higher in the serum of patients with nocturia; however, the reason remains unknown. Here, we investigated the circadian rhythm of fatty acid metabolites and their effect on voiding in mice. WT and Clock mutant (ClockΔ19/Δ19) mice, a model for nocturia with circadian rhythm disorder, were used. Levels of serum PEA, 9-HODE, and 4-HDoHEl were measured every 8 h using LC/MS. Voiding pattern was recorded using metabolic cages after administration of PEA, 9-HODE, and 4-HDoHE to WT mice. Levels of serum PEA and 9-HODE fluctuated with circadian rhythm in WT mice, which were lower during the light phase. In contrast, circadian PEA and 9-HODE level deteriorated or retreated in ClockΔ19/Δ19 mice. Levels of serum PEA, 9-HODE, and 4-HDoHE were higher in ClockΔ19/Δ19 than in WT mice. Voiding frequency increased in PEA- and 4-HDoHE-administered mice. Bladder capacity decreased in PEA-administered mice. The changes of these bladder functions in mice were similar to those in elderly humans with nocturia. These findings highlighted the novel effect of lipids on the pathology of nocturia. These may be used for development of biomarkers and better therapies for nocturia.
... Interestingly, unsaturated FA appear to be involved in lipid ordering and lipid raft stability, also influencing inflammatory effects, given that lipid rafts are platforms for the assembly and function of many signaling pathways [9]. The role of dietary lipids has been debated and supported for gut [10,11] and brain functions [12,13]; moreover, the ability of EPA and DHA to reduce blood pressure and inflammatory processes has been reported [14]. In cells, the membrane FA composition influences the inflammatory response by affecting the production of inflammatory mediators [15]. ...
Full-text available
In this review, the role of fatty acids (FA) in human pathological conditions, infertility in particular, was considered. FA and FA-derived metabolites modulate cell membrane composition, membrane lipid microdomains and cell signaling. Moreover, such molecules are involved in cell death, immunological responses and inflammatory processes. Human health and several pathological conditions are specifically associated with both dietary and cell membrane lipid profiles. The role of FA metabolism in human sperm and spermatogenesis has recently been investigated. Cumulative findings indicate F2 isoprostanes (oxygenated products from arachidonic acid metabolism) and resolvins (lipid mediators of resolution of inflammation) as promising biomarkers for the evaluation of semen and follicular fluid quality. Advanced knowledge in this field could lead to new scenarios in the treatment of infertility.
Full-text available
There is a growing interest to understand the capacity of farmed fish species to biosynthesise the physiologically important long-chain (≥C20) n-3 and n-6 polyunsaturated fatty acids (LC-PUFAs), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), from their C18 PUFA precursors available in the diet. In fish, the LC-PUFA biosynthesis pathways involve sequential desaturation and elongation reactions from α-linolenic acid (ALA) and linoleic acid (LA), catalysed by fatty acyl desaturases (Fads) and elongation of very long-chain fatty acids (Elovl) proteins. Our current understanding of the grass carp (Ctenopharyngodon idella) LC-PUFA biosynthetic capacity is limited despite representing the most farmed finfish produced worldwide. To address this knowledge gap, this study first aimed at characterising molecularly and functionally three genes (fads2, elovl5 and elovl2) with putative roles in LC-PUFA biosynthesis. Using an in vitro yeast-based system, we found that grass carp Fads2 possesses ∆8 and ∆5 desaturase activities, with ∆6 ability to desaturase not only the C18 PUFA precursors (ALA and LA) but also 24:5n-3 to 24:6n-3, a key intermediate to obtain DHA through the “Sprecher pathway”. Additionally, the Elovl5 showed capacity to elongate C18 and C20 PUFA substrates, whereas Elovl2 was more active over C20 and C22. Collectively, the molecular cloning and functional characterisation of fads2, elovl5 and elovl2 demonstrated that the grass carp has all the enzymatic activities required to obtain ARA, EPA and DHA from LA and ALA. Importantly, the hepatocytes incubated with radiolabelled fatty acids confirmed the yeast-based results and demonstrated that these enzymes are functionally active.
Full-text available
Polyunsaturated fatty acids (PUFAs) are a class of fatty acids that are closely associated with the development and function of the brain. The most abundant PUFA is docosahexaenoic acid (DHA, 22:6 n-3). In humans, low plasmatic concentrations of DHA have been associated with impaired cognitive function, low hippocampal volumes, and increased amyloid deposition in the brain. Several studies have reported reduced brain DHA concentrations in Alzheimer’s disease (AD) patients’ brains. Although a number of epidemiological studies suggest that dietary DHA consumption may protect the elderly from developing cognitive impairment or dementia including AD, several review articles report an inconclusive association between omega-3 PUFAs intake and cognitive decline. The source of these inconsistencies might be because DHA is highly oxidizable and its accessibility to the brain is limited by the blood–brain barrier. Thus, there is a pressing need for new strategies to improve DHA brain supply. In the present study, we show for the first time that the intranasal administration of nanovectorized DHA reduces Tau phosphorylation and restores cognitive functions in two complementary murine models of AD. These results pave the way for the development of a new approach to target the brain with DHA for the prevention or treatment of this devastating disease.
Fatty acids are critical bioactives for fetal and neonatal development. Premature delivery and current nutritional strategies pose several challenges in restoring fatty acid balance in the preterm infant. The impact on fatty acid balance and outcomes using lipid emulsions, enteral nutrition, and enteral supplements are reviewed, including a summary of the most recent large clinical trials of enteral fatty acid supplementation for the preterm infant. Research gaps remain in successfully implementing nutritional strategies to optimize fatty acid status in preterm infants.
The abundance of docosahexaenoic acid (DHA) in brain membrane phospholipids has stimulated studies to explore its role in neurological functions. Upon released from phospholipids, DHA undergoes enzymatic reactions resulting in synthesis of bioactive docosanoids and prostanoids. However, these phospholipids are also prone to non-enzymatic reactions leading to more complex pattern of metabolites. A non-enzymatic oxidized product of DHA, 4(RS)-4-F4t-Neuroprostane (44FNP), has been identified in cardiac and brain tissues. In this study, we examined effects of the 44FNP on oxidative and inflammatory responses in microglial cells treated with lipopolysaccharide (LPS). The 44FNP attenuated LPS-induced production of reactive oxygen species (ROS) in both primary and immortalized microglia (BV2). It also attenuated LPS-induced inflammation through suppressing NFκB-p65 and levels of iNOS and TNFα. In addition, 44FNP also suppressed LPS-induced mitochondrial dysfunction and upregulated the Nrf2/HO-1 antioxidative pathway. In sum, these findings with microglial cells demonstrated neuroprotective effects of this 44FNP and shed light into the potential of nutraceutical therapy for neurodegenerative diseases.
Docosahexaenoic acid (DHA) has numerous functions in adjusting the organic health and pragmatic value in medicine and food field. In this study, we compared glycerol and glucose as the only carbon source for DHA production by Aurantiochytrium. When the glycerol concentration was 120 g/L, the maximum DHA yield was 11.08 g/L, and the DHA yield increased significantly, reaching 47.67% of the total lipid content. When the cells grew in glucose, the DHA proportion was 37.39%. Transcriptome data showed that the glycolysis pathway and tricarboxylic acid cycle in Aurantiochytrium were significantly inhibited during glycerol culture, which promoted the tricarboxylic acid transport system and was conducive to the synthesis of fatty acids by acetyl coenzyme A; glucose as substrate activated fatty acid synthesis (FAS)pathway and produced more saturated fatty acids, while glycerol as substrate activated polyketide synthase (PKS)pathway and produced more long-chain polyunsaturated fatty acids. This laid a foundation for fermentation metabolism regulation and molecular transformation.
Full-text available
Introduction: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)-associated coronavirus pandemic has posed a global health emergency. Methods: We focused on clinical features, diagnostic evaluation, management, infection prevention, and safe handling of deceased bodies with suspected and confirmed COVID-19. Results: The case fatality rate is estimated at around 3%. Diagnosis is by the demonstration of the virus in respiratory secretions by RT-PCR mainly. Common laboratory findings include average/low white cell counts with elevated C-reactive protein (CRP). The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndromes (MODS). Conclusion: Treatment is primarily supportive; the role of antiviral agents is yet to be established. Prevention entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions.
Full-text available
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the main and most prevalent side effects of chemotherapy, significantly affecting the quality of life of patients and the course of chemotherapeutic treatment. Nevertheless, despite its prevalence, the management of the CIPN is considered particularly challenging, with this condition often being perceived as very difficult or even impossible to prevent with currently available agents. Therefore, it is imperative to find better options for patients diagnosed with this condition. While the search for the new agents must continue, another opportunity should be taken into consideration—repurposing of the already known medications. As proposed, acetyl-L-carnitine, vitamins (group B and E), extracts of medical plants, including goshajinkigan, curcumin and others, unsaturated fatty acids, as well as the diet composed of so-called “sirtuin-activating foods”, could change the typical way of treatment of CIPN, improve the quality of life of patients and maintain the continuity of chemotherapy. This review summarizes currently available data regarding mentioned above agents and evaluates the rationale behind future research focused on their efficacy in CIPN. View Full-Text
Intestinal microbiota and metabonomic were integrated to investigate the efficiency of non-saponification or saponification astaxanthin (N-Asta or S-Asta) derived from Penaeus sinensis by-products on alleviating paracetamol (PCM)-induced oxidative stress. Pre-treated...
Full-text available
High levels of docosahexaenoic acid (DHA) in the phospholipids of mammalian brain have generated increasing interest in the search for its role in regulating brain functions. Recent studies have provided evidence for enhanced protective effects when DHA is administered in combination with phytochemicals, such as quercetin. DHA and quercetin can individually suppress lipopolysaccharide (LPS)–induced oxidative/inflammatory responses and enhance the antioxidative stress pathway involving nuclear factor erythroid-2 related factor 2 (Nrf2). However, studies with BV-2 microglial cells indicated rather high concentrations of DHA (IC50 in the range of 60–80 µM) were needed to produce protective effects. To determine whether quercetin combined with DHA can lower the levels of DHA needed to produce protective effects in these cells is the goal for this study. Results showed that low concentrations of quercetin (2.5 µM), in combination with DHA (10 µM), could more effectively enhance the expression of Nrf2 and heme oxygenase 1 (HO-1), and suppress LPS–induced nitric oxide, tumor necrosis factor-α, phospho-cytosolic phospholipase A2, reactive oxygen species, and 4-hydroxynonenal, as compared to the same levels of DHA or quercetin alone. These results provide evidence for the beneficial effects of quercetin in combination with DHA, and further suggest their potential as nutraceuticals for improving health.
Full-text available
Background Resolution of inflammation is an active and dynamic process after surgery. Maresin 1 (MaR1) is one of a growing number of specialised pro-resolving lipids biosynthesised by macrophages that regulates acute inflammation. We investigated the effects of MaR1 on postoperative neuroinflammation, macrophage activity, and cognitive function in mice. Methods Adult male C57BL/6 (n=111) and Ccr2RFP/+Cx3cr1GFP/+ (n=54) mice were treated with MaR1 before undergoing anaesthesia and orthopaedic surgery. Systemic inflammatory changes, bone healing, neuroinflammation, and cognition were assessed at different time points. MaR1 protective effects were also evaluated using bone marrow derived macrophage cultures. Results MaR1 exerted potent systemic anti-inflammatory effects without impairing fracture healing. Prophylaxis with MaR1 prevented surgery-induced glial activation and opening of the blood–brain barrier. In Ccr2RFP/+Cx3cr1GFP/+ mice, fewer infiltrating macrophages were detected in the hippocampus after surgery with MaR1 prophylaxis, which resulted in improved memory function. MaR1 treatment also reduced expression of pro-inflammatory cell surface markers and cytokines by in vitro cultured macrophages. MaR1 was detectable in the cerebrospinal fluid of older adults before and after surgery. Conclusions MaR1 exerts distinct anti-inflammatory and pro-resolving effects through regulation of macrophage infiltration, NF-κB signalling, and cytokine release after surgery. Future studies on the use of pro-resolving lipid mediators may inform novel approaches to treat neuroinflammation and postoperative neurocognitive disorders.
Full-text available
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the brain's resident macrophages (microglia) and other immune cells has been demonstrated to exacerbate both amyloid and tau pathology and may serve as a link in the pathogenesis of the disorder. In the following review, we provide an overview of inflammation in AD and a detailed coverage of a number of microglia-related signaling mechanisms that have been implicated in AD. Additional information on microglia signaling and a number of cytokines in AD are also reviewed. We also review the potential connection of risk factors for AD and how they may be related to inflammatory mechanisms.
Full-text available
Brain development requires a massive increase in brain lipogenesis and accretion of the essential omega-3 fatty acid docosahexaenoic acid (DHA). Brain acquisition of DHA is primarily mediated by the transporter Major Facilitator Superfamily Domain containing 2a (Mfsd2a) expressed in the endothelium of the blood-brain barrier (BBB) and other abundant cell types within the brain. Mfsd2a transports DHA and other polyunsaturated fatty acids (PUFAs) esterified to lysophosphatidylcholine (LPC-DHA). However, the function of Mfsd2a and DHA in brain development is incompletely understood. Here, we demonstrate, using vascular endothelial-specific and inducible vascular endothelial-specific deletion of Mfsd2a in mice, that Mfsd2a is uniquely required postnatally at the BBB for normal brain growth and DHA accretion, with DHA deficiency preceding the onset of microcephaly. In Mfsd2a-deficient mouse models, a lipidomic signature was identified that is indicative of increased de novo lipogenesis of PUFAs. Gene expression profiling analysis of these DHA-deficient brains indicated that sterol regulatory-element binding protein (Srebp)-1 and Srebp-2 pathways were highly elevated. Mechanistically, LPC-DHA treatment of primary neural stem cells down-regulated Srebp processing and activation in a Mfsd2a-dependent fashion, resulting in profound effects on phospholipid membrane saturation. In addition, Srebp regulated the expression of Mfsd2a. These data identify LPC-DHA transported by Mfsd2a as a physiological regulator of membrane phospholipid saturation acting in a feedback loop on Srebp activity during brain development.
Full-text available
Brain development is a sequential anatomical process characterised by specific well-defined stages of growth and maturation. One of the fundamental and necessary events in the normal development of the central nervous system in vertebrates is the formation of a myelin sheath. This process is influenced by dietary lipids. A number of researches have indicated that the administration of a diet, deficient in essential fatty acids during development causes hypomyelination in the brain. Brain lipids determine the localization and function of proteins in the cell membrane and in doing so regulate synaptic signalling in neurons. Lipids may also function as transmitters and relay signals from the membrane to intracellular compartments or to other cells. Several experimental studies have suggested a crucial role of n-3 polyunsaturated fatty acids in membrane formation, as well as clinical role of glycerolipids, glycerophospholipids, and sphingolipids in the attenuation of depression- and anxiety-related behaviours. Hence it can be assumed that polyunsaturated fatty acids may also offer new treatment options (for example, targeted dietary supplementation or pharmacological interference with lipid-regulating enzymes). These lipids could be exploited for improved prevention and treatment. A very interesting and emerging approach in this direction is through ‘Lipidomics’ which is a relatively recent research field that has been driven by rapid advances in technologies such as mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectroscopy, dual polarisation interferometry and computational methods, coupled with the recognition of the role of lipids in many metabolic diseases such as obesity, atherosclerosis, stroke, hypertension and diabetes.
Full-text available
Cerebral ischemia/reperfusion (I/R) injury is a critical factor leading to a poor prognosis for ischemic stroke patients. ω-3 fatty acid supplements taken as part of a daily diet have been shown to improve the prognosis of patients with ischemic stroke. In this study, we aimed to investigate the potential effects of resolvin D2 (RvD2), a derivative of ω-3 fatty acids, and its possible advantage on cerebral I/R injury in rats. Cerebral I/R caused by middle cerebral artery occlusion and reperfusion (MCAO/R) was established in Sprague-Dawley rats. First, in rats fed a regular diet, the MCAO/R stimulus led to a significant decrease in endogenous production of RvD2. Exogenous supply of RvD2 via intraperitoneal injection reversed MCAO/R-induced brain injury, including infarction, inflammatory response, brain edema, and neurological dysfunction. Meanwhile, RvD2 reversed the MCAO/R-induced decrease in the protein level of GPR18, which has been identified as a receptor for RvD2, especially in neurons and brain microvascular endothelial cells (BMVECs). Furthermore, RvD2 exerted rescue effects on MCAO/R-induced neuron and BMVEC death. Moreover, GPR18 antagonist O-1918 could block the rescue effects of RvD2, possibly at least partially though the GPR18-ERK1/2-NOS signaling pathway. Finally, compared with ω-3 fatty acid supplements, RvD2 treatment had a better rescue effect on cerebral infarction, which may be due to the MCAO/R-induced decrease in 5-lipoxygense phosphorylation and subsequent RvD2 generation. In conclusion, compared with ω-3 fatty acids, RvD2 may be an optimal alternative and complementary treatment for ischemic stroke patients with recanalization treatment.
Full-text available
Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes related to their structural diversity, and based on this can be broadly classified into five categories; fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Different lipid classes play major roles in neuronal cell populations; they can be used as energy substrates, act as building blocks for cellular structural machinery, serve as bioactive molecules, or a combination of each. In amyotrophic lateral sclerosis (ALS), dysfunctions in lipid metabolism and function have been identified as potential drivers of pathogenesis. In particular, aberrant lipid metabolism is proposed to underlie denervation of neuromuscular junctions, mitochondrial dysfunction, excitotoxicity, impaired neuronal transport, cytoskeletal defects, inflammation and reduced neurotransmitter release. Here we review current knowledge of the roles of lipid metabolism and function in the CNS and discuss how modulating these pathways may offer novel therapeutic options for treating ALS.
Background: It has long been believed that DHA supplementation increases plasma EPA via the retroconversion pathway in mammals. However, in rodents this increase in EPA is likely due to a slower metabolism of EPA, but this has never been tested directly in humans. Objective: The aim of this study was to use the natural variations in 13C:12C ratio (carbon-13 isotopic abundance [δ13C]) of n-3 PUFA supplements to assess n-3 PUFA metabolism following DHA or EPA supplementation in humans. Methods: Participants (aged 21.6 ± 2.2 y) were randomly assigned into 1 of 3 supplement groups for 12 wk: 1) olive oil control, 2) ∼3 g/d DHA, or 3) ∼3 g/d EPA. Blood was collected before and after the supplementation period, and concentrations and δ13C of plasma n-3 PUFA were determined. Results: DHA supplementation increased (P < 0.05) plasma EPA concentrations by 130% but did not affect plasma δ13C-EPA (-31.0 ± 0.30 to -30.8 ± 0.19, milliUrey ± SEM, P > 0.05). In addition, EPA supplementation did not change plasma DHA concentrations (P > 0.05) but did increase plasma δ13C-DHA (-27.9 ± 0.2 to -25.6 ± 0.1, P < 0.05) toward δ13C-EPA of the supplement (-23.5 ± 0.22). EPA supplementation increased plasma concentrations of EPA and docosapentaenoic acid (DPAn-3) by 880% and 200%, respectively, and increased plasma δ13C-EPA (-31.5 ± 0.2 to -25.7 ± 0.2) and δ13C-DPAn-3 (-28.9 ± 0.3 to -25.0 ± 0.1) toward δ13C-EPA of the supplement. Conclusions: In this study, we show that the increase in plasma EPA following DHA supplementation in humans does not occur via retroconversion, but instead from a slowed metabolism and/or accumulation of plasma EPA. Furthermore, substantial amounts of supplemental EPA can be converted into DHA. δ13C of n-3 PUFA in humans is a powerful and underutilized tool that can track dietary n-3 PUFA and elucidate complex metabolic questions. This trial was registered at as NCT03378232.
Attention deficit hyperactivity disorder (ADHD) is considered the most common behavioural disorder in school-age children. ADHD is a complex and multifactorial disorder characterised by a variety of symptoms, including concentration problems, excessive motor activity and impulsivity which interferes with execution of simple school tasks. Diagnosis has been essentially subjective, since no specific laboratory tests are available. However, ADHD remains overdiagnosed, probably due to social pressures for children to be successful in school from an early age, which leads parents to seek medical support. Although therapeutic approaches for ADHD have been essentially pharmacologic, in recent years several studies were performed to investigate the role of nutrition, especially omega 3 polyunsaturated fatty acid (omega 3-PUFA), in the development and treatment of this disorder. In this review, the authors gathered the most relevant evidence regarding omega 3-PUFA, mainly docosahexaenoic acid, as coadjutant or as a single therapy, in the management of ADHD symptoms. The authors also reviewed this disorder's current medical and therapeutic features.